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ABSTRACT 
 
Functional Characterization of Azinomycin  
Biosynthetic Enzymes. (August 2012) 
Hillary Chidi Agbo, B.Sc., University of Nigeria, Nsukka 
Chair of Advisory Committee:  Dr. Coran M.H. Watanabe 
 
 Azinomycins A and B are antitumor compounds isolated from soil bacteria, 
Streptomyces sahachiroi. The azinomycin structure contains an unusual aziridine [1,2a] 
pyrrolidine ring and an epoxyvaline moiety which are used in forming DNA cross-links. 
The biosynthetic gene cluster of azinomycin B has been characterized but the 
biosynthetic routes to these intermediates and overall architecture of this compound is 
not well understood. 
This work investigates the role of aziW, a lysW homologue in azinomycin 
biosynthesis. Gene replacement of aziW by homologous exchange abolished the 
production of azinomycin thereby implicating the gene in azinomycin biosynthesis. 
Complementation of aziW in the mutant strain, however, did not restore production of 
this natural product as observed by HPLC analysis, which suggests that aziW as well as 
genes downstream could be responsible for lack of azinomycin production. Sequence 
analysis of aziW suggests co-transcription with the downstream genes which are 
homologous to lysine biosynthetic genes in T. thermophilus. The mRNA expression 
profile of the genes downstream of aziW exhibited a down-regulation or transcription 
 iv 
termination for these genes which appear to be in the same operon. The impact is 
stronger the further away the gene is from aziW. Negative lysine auxotrophy test showed 
that this gene is not involved in lysine biosynthhesis but is crucial to azinomycin 
biosynthesis. This dissertation also discusses the investigation of the role of ORF10, a 
dehydrogenase which is located at the terminal end of the gene cluster. Gene disruption 
of ORF10 had no effect in azinomycin production but established the boundary of the 
azinomycin gene cluster. AziC9 was charaterized as an authentic cytochrome P450 
through gene expression in E.coli, purification, carbon monoxide binding and activity 
assay with a putative substrate. 
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CHAPTER I 
INTRODUCTION   
 
NATURAL PRODUCTS 
Humans are inventive and adaptive; they have found ways of treating various 
illnesses since life began on earth. In the pre-historic era, plants and their extracts were 
the dominant sources of active medicinal compounds. Plant-derived metabolites were 
used as flavors for food, colorants, fragrances, sweeteners. Natural products, as the term 
is applied in this write-up, refer mostly to biologically active natural products and their 
precursors. The discovery of natural products of microbial origin started with the use of 
molds and warm soil in the treatment of wounds and infections. The birth of modern 
medicine was heralded by Sir Alexander Fleming’s serendipitous discovery in 1928 of 
the β-lactam antibiotic, penicillin, produced by the fungus Penicillium notatum and the 
follow-up clinical studies in the 1940s.1 The advance in science and technology has 
overcome the barriers met by earlier efforts in the discovery of natural products. Natural 
products, their derivatives, and natural product- inspired compounds remain invaluable 
to the pharmaceutical industry and medicine in general. In the period between 1981 and 
2010, the FDA approved the use of 1073 small molecules as drugs; ~60% of these were 
natural products, their derivatives, or natural product-inspired compounds (Figure 1).2 
____________ 
This dissertation follows the style of Biochemistry. 
 
 2 
Romidepsin (Figure 2) is one of the six antitumor agents approved in 2010. It is a 
histone deacetylase inhibitor (HDAC) and a microbial natural product.  Although the 
total synthetic route exists for this compound, it is still being produced by fermentation 
of Chromobacterium violaceum.3-7  This approval came after a roughly 20-year shift by 
big pharmaceutical companies from natural product-based discovery programs.2  
 
          
Figure 1.Distribution of approved small molecule drug sources from 1981 to 2010.2 
N, natural product; NB, Natural product botanical (in general these have been recently approved); ND, 
derived from a natural product and usually a semisynthetic modification; S, totally synthetic drug often 
found by random screening/modification of an existing agent; S*, made by total synthesis, but the 
pharmacophore is/was from a natural product; NM subcategory, natural product mimic. 
 
 
The discussion of natural products in this era cannot be complete without the 
mention of two very important drugs, taxol and vancomycin (Figure 2). The story of 
these two drugs has been a motivation to both researchers and investors, who are in 
constant search of another blockbuster drug.  Taxol was discovered in 1967, isolated 
N,59,6% 
NB,5,0% 
ND, 299,28% 
S,387,36% 
S/NM,146,14% 
S*,55,5% 
S*/NM,122,11% 
N 
NB 
ND 
S 
S/NM 
S* 
S*/NM 
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from the Pacific yew tree and is used in treating soft-tissue cancer.8-9 Between 1967 and 
1993, taxol was almost completely produced from the bark of the Pacific yew. A 
semisynthetic route was later established, and taxol generated $1.6 billion in annual sales 
to Bristol-Myers Squibb in 2000.10-12 Vancomycin, on the other hand, is a glycopeptide 
antibiotic produced by the soil organism, Amycolatopsis orientalis. It is used as the last 
line of defense in treating methicillin-resistant Staphylococcus aureus (MRSA) and 
penicillin-resistant Streptococcus pneumonia infections.13 
 
Figure 2.Structures of some natural products used as drugs. 
 
NATURAL PRODUCT BIOSYNTHESIS 
Nature is the best chemist ever known and carries out a plethora of chemical 
reactions required for sustaining living organisms. While this primary metabolism is 
indispensible to the daily existence of the organism, the need arises for these organisms 
to carry out chemical reactions through clearly defined pathways during adverse 
conditions like starvation, disease and the presence of chemical agents. Secondary 
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metabolites represent a pool of chemical structures ranging from very simple to complex 
architectures. The products and intermediates of primary metabolism form the building 
blocks; they are fed into the biosynthetic pathways of these secondary metabolites and 
form the basis of secondary metabolic products classification. In 1907, James Collie, a 
chemist at London University proposed his ideas on the biosynthesis of polyphenols.14 
At the time, there were no biological chemists, and organic chemists do not have much 
idea of reaction pathways in the living system. His ideas were dismissed as premature 
and overly ambitious. In 1917, Robert Robinson proposed a scheme (Figure 3A) for the 
biosynthesis of tropinone, a synthetic precursor to atropine, which is an extract from 
plant and serves as drug with a variety of effects.15–16  The chemists of Robinson’s time 
were more receptive to his ideas and his proposal was accepted. Arthur Birch, the 
chemist who coined the term “poly ketides,” had his early training in Robinson’s 
laboratory at Oxford. In 1950, he proposed the biosynthetic route for the aromatic 
polypeptide, 6-methylsalyicylic acid (Figure 3B), produced by the fungus, Penicillium 
patulum.17,18 The study of natural product biosynthesis has been enhanced by the 
development of radioactive-labeling studies, NMR and MS spectroscopies, and more 
recently, advancement in the genomic and proteomic technologies. Natural products are 
biosynthesized through limited but complex pathways including the fatty acid synthases 
(FAS), the polyketides synthases (PKS), the non-ribosomal peptide synthetases (NRPS), 
terpenes and alkaloids pathways.  
 5 
 
Figure 3.Proposed routes to natural product biosynthesis. (A) Robinson’s biomimetic synthesis of 
tropinone. (B) Birch’s route to biosynthesis of 6-methylsalicylic acid. 
 
FATTY ACIDS AND POLYKETIDES 
Fatty acid synthases (FAS) are multi-functional enzyme complexes that catalyze 
the synthesis of fatty acids through a decaboxylative Clasien condensation of the starter 
unit, acetate, and a decarboxylated malonyl-unit by the action of the keto synthase (KS) 
domain.19-21 The extended unit is released from the enzyme and further converted to β–
hydroxy thioester by the keto reductase (KR) domain. A β-unsaturated thioester is 
formed from the β–hydroxy thioester by the loss of a water molecule by the action of the 
dehydratase (DH) domain. The enoyl reductase (ER) domain then reduces the above 
intermediate to produce a saturated fatty acid (Figure 4). This sequence of reactions is 
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repeated, and the growing fatty acid chain is transferred between active sites while 
covalently attached to the phosphopantetheinyl arm of the acyl carrier protein (ACP) 
until the desired chain length is reached. The mature fatty acid is then released by the 
action of the thioesterase (TE) domain.  
The fatty acid synthases (FAS) resemble the polyketide systems in that they 
share some catalytic domains. However, the PKSs are deficient in some of the reductive 
catalytic domains necessary for the saturated alkyl chains produced in FAS systems. The 
core domains of PKS system are the keto synthase (KS), acyltransferase (AT), and 
thiolation (T) domain. The structural diversity of polyketides is controlled by the 
variation in the choice of starter (acetyl-CoA, malonyl-CoA, methylmalonyl-CoA) and 
the extender units, as well as by the number of condensations and reduction cycles. The 
two main types of PKS systems found in bacteria are the type I & II PKSs. Type I PKSs 
are multi-domain proteins encoded by single gene, whereas type II PKSs are trans-acting 
iterative protein complexes in which each domain is encoded by one gene.22 The 
cis/trans wiring of the domains of type I and type II PKS systems are illustrated in 
Figure 5. Catalytic domains in type II PKSs are used multiple times during chain 
elongation, whereas those in type I PKSs are only used once per catalytic cycle.   
 7 
 
Figure 4.Reaction scheme for the FAS system. (A) Acetyl-CoA and Malonyl-CoA units (B) KS, AT 
domains that catalyze the decaboxylative Claisen condensation of the starter units; KR, DH, ER modify 
unit, TE release product. 
 
 
A classical example of type I or modular PKS is the erythromycin PKS. The 
structural genes responsible for synthesizing the first macrolide intermediate, 6-
deoxyerythronolide B (6-DEB), are three giant open reading frames coding for 
multienzyme polypeptides, 6-deoxyerythronolide B synthase (DEBS) 1, 2 and 3.23-25 
Each of the DEBS proteins contains two functional modules, which in turn contain the 
 8 
core domains, KS, AT and ACP (Figure 6). These modules contain variable sets of 
domains, KR, DH and ER, which are required for the modification of the keto group. 
The intermediate, 6-DEB, is released by the TE domain in DEBS 3 and further modified 
by other tailoring enzymes to produce erythromycin B. There are unusual cases of 
aromatic compounds derived from type I PKSs in which either the domains or modules 
are used in iterative manner.26-29 The 6-methylsalicylic acid synthase (6-MSAS) is an  
 
                
Figure 5.Comparison of the domain arrangement in type I and II PKS systems. (A) Type I PKS system, 
domains are connected in cis; (B) Type II PKS system, domains are trans-acting.17 
 
 
example of an iterative type I PKS. 6-MSAS contains KS, MAT, DH, KR, and ACP 
domains in that order, and forms 6-MSA from one molecule of acetate starter unit and 
three molecules of malonate extender units.18 What is remarkable about the 6-MSAS 
(Figure 7a) is that it lacks the thioesterase (TE) domain, so that release of the chain from 
the PKS occurs not by TE domain-mediated hydrolysis but by some other mechanism. It 
was initially proposed that the release of the product proceeded through a ketene 
intermediate.18 The actual domain involved in the release of the product was identified 
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two decades later.30 The 6-MSA is released hydrolytically from 6-MSAS by the action 
of the domain initially called DH but later renamed thioester hydrolase (TH) domain. 
Type III PKSs do not share domains with FAS and are seen as a unique type of PKS. 
 
 
 
 
 Figure 6.Biosynthesis of 6-deoxyerythronolide B. 
 
 Examples of type III PKSs are the chalcone synthase (CHS), a plant polyketide 
synthase that uses p-coumarin-CoA as the starter unit, and acridone synthase (ACS) 
(Figure 7b), which uses N-methylanthraniloyl-CoA as the starter unit.31-34 Chalcones are 
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natural phenols and form the central core of a variety of biologically active 
compounds.35,36 Acridone forms the scaffold for a variety of synthetic compounds with 
interesting pharmacological properties.37,38 Although the initial steps of Claisen 
condensation and cyclisation in CHS resembles that of type I and II PKS systems, there 
are differences in the mode of transfer of the intermediates among active sites. The PKSs 
use the phosphopantetheine arm of ACP to shuttle substrates and intermediates through 
the active sites, whereas CHS uses CoA thioesters directly.39  
 
                    
Figure 7(a).Biosynthetic pathway of fungal polyketide 6-methylsalicylic acid. 
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The decarboxylation, condensation, cyclization and aromatization events in CHS 
are all carried out in a single active site, in contrast to type I or II PKSs.39 
 
 
Figure 7(b).Illustration of type III PKS system. 
 
RIBOSOMAL PEPTIDES 
Ribosomal peptides are natural products that are produced by the ribosomal 
machinery. They exhibit broad structural and functional diversity.  Unlike non-ribosomal 
peptides, their structural diversity is limited by the pool of amino acid residues 
accessible to ribosomal peptide enzymes. There is no evidence yet of the ability of the 
ribosomal peptide machinery to explore amino acids beyond the standard twenty 
proteinogenic ones. In spite of this limitation, ribosomal peptides display as much 
structural diversity as non-ribosomal peptides because of the extensive post-translational 
modification found in the ribosomal peptide system. Some modifications that were 
initially thought to be unique to the non-ribosomal peptides are also found in the 
ribosomal system. Compared to the non-ribosomal system, the ribosomal peptide system 
offers a simple platform for the modification of the natural product. The manipulation of 
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a few codons for ribosomal peptide sequence results in an increase in structural and 
functional diversity; this is in contrast to the non-ribosomal peptides, which require 
extensive genetic engineering to effect changes in structure. 40, 41  In the ribosomal 
peptide synthesis pathway, short peptide precursors are translated in the ribosome 
followed by modification by enzymes to produce very complex natural products.42 The 
modifications can be so extensive, for example in pyrroloquinoline quinone (Figure 8), 
that the natural product is no longer readily recognizable as derived from amino acids. 
Another example of a ribosomal peptide natural product is the lantibiotics (Figure 8), 
which are produced by a number of streptococcus and streptomyces species and are used 
in food preservation and treatment of infection in human.43 
A generic form of the ribosomal peptide biosynthesis is shown in Figure 9 below. 
The gene for a precursor peptide is usually clustered with the modifying enzyme. 
Following translation, the precursor peptide is post-translationally modified, and an 
active natural product is formed.42 One common post-translational modification of 
amino acid residues is the dehydration of serine and threonine. This modification results 
in intermediates that can react by both intramolecular and intermolecular mechanisms to 
form well-known ribosomal peptides like lanthionine, nisin and subtilin.44,45 Another 
known side-chain modification is prenylation which enhances their lipophilicity and 
helps in membrane targeting.46 Disulfide bond formation is common to proteins and 
small peptides. In ribosomal peptides, it plays a role in constraining small peptide 
sequences into active conformations.47 Conopeptides are biologically potent ribosomal 
peptides that contain multiple disulfide bridges; incorrect disulfide bridging during 
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synthesis or disruption of disulfide bridges by mutagenesis has been shown to inactivate 
this class of compounds.48  
 
 
Figure 8.Structures of some ribosomal natural products.  
 
One common feature of ribosomally synthesized peptides is proteolytic cleavage 
from precursor peptides. The primary site for proteolysis is the N-terminus of the peptide 
(Figure 9); however, pyrroloquinoline quinone (Figure 8) and cyanobactins are cases in 
which both N-terminal and C-terminal proteolytic cleavage occur.49  Proteolysis has 
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been shown, in some cases to activate the peptide, and is in some cases tightly coupled 
to the ABC transport proteins for export from the cytoplasm.50-55 Other documented 
types of main-chain modification of ribosomal peptides are macrocyclization, 
formylation, lactone formation, addition of a nucleotide base and glycosylation.56-60     
 
      
 Figure 9.Generic steps in bacterial ribosomal peptide biosynthesis. 
 
NON-RIBOSOMAL PEPTIDES (NRP)           
Bacteria and fungi use large multifunctional enzymes to produce peptide natural 
products of diverse structure and broad biological activity. The large multifunctional 
enzymes involved in the biosynthesis of non-ribosomal peptides are called Non-
Ribosomal Peptide Synthetases (NRPS). Unlike the ribosomal peptides, the non-
ribosomal peptides are produced independent of messenger RNA (mRNA) and the 
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ribosomal machinery. Although similarities exist between the ribosomally and non-
ribosomally derived peptide natural products, there are differences in the architecture 
and the pool of over 500-building blocks available to NRPSs.61 A number of NRPs 
contain non-proteinogenic amino acid residues and other molecules like fatty and α-
hydroxyl acids that are not usually found in ribosomally synthesized natural products.62-
64 The structural diversity provided by the large pool of precursors contributes to the 
broad clinical application of NRP natural products. 
In terms of the arrangement of the catalytic domains, NRPSs differ remarkably 
from ribosomal peptide systems but resemble the type I fatty acid system. Individual 
catalytic domains are stitched together into modules that are responsible for 
incorporation of the building blocks into the growing polypeptide chain.65 The core 
components of a module are the adenylation (A), peptidyl carrier protein (PCP or T), and 
condensation (C), domains except for the initiation module, which lacks a C-domain. In 
addition to the core domains, there exists a number of tailoring enzymes that aid in the 
maturation of the NRP product.  
The selection of the building blocks to be added to the NRPS system is similar to 
the ribosomal synthesis of protein. In the same way that the amino acid t-RNA (aa-
tRNA) synthetase charges the amino acid residue to be incorporated into the growing 
peptide chain, the adenylation of an amino acid or other substrate activates it for 
incorporation into the growing chain. These enzymes are structurally unrelated despite 
the similarity in the enzymatic activities of the A-domain of NRPS and aa-tRNA 
synthetase.66 Activated amino acid is transported to the PCP domain, where it gets 
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covalently tethered to the phophopantetheinyl cofactor as a thioester.67 The thioester acts 
like a flexible arm that allows the movement of the bound amino acyl and peptidyl 
substrates between different catalytic centers. The condensation domains are responsible 
for the formation of the peptide bonds between the PCP-bound amino acyl substrates of 
adjacent modules.68 Occasionally, the modules contain tailoring domains: for example  
formylation (F), oxidation (O), reduction (Red), N-methylation (NMT), epimerization 
(E) and cyclization (Cy). The synthesis of NRP is a highly controlled process that starts 
with substrate-specific activation and incorporation that is dictated by the NRPS 
template. The termination of the synthesis occurs in an ordered sequence and is signaled 
by the presence of a thioesterase domain (TE) in the termination module. Figure 10 
Illustrates the arrangement of NRPS modules in the biosynthesis of surfactin A. 
Surfactin A synthetase is made up of seven modules, each of which contains the core 
domains C, A and T. Modules 3 and 6 contain an epimerization domain each, and the 
terminal module 7 contains a TE domain that carries out the cyclization and release of 
the natural product. Because fungi often use a single NRPS for natural product 
biosynthesis, these multifunctional enzymes can reach a staggering size. Tolypocladium 
niveum uses a single NRPS of about 1.6 MDa, which contains 11 modules for the 
synthesis of cyclosporine A (Figure 11), an immunosuppressant used in the prevention 
and treatment of graft-versus-host reactions in bone-marrow transplantation and in 
prevention of rejection of kidney, heart and liver after transplants.69 
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  Figure 10.Illustration of surfactin A biosynthesis. 
 
In bacteria, the modules are usually organized into operons, which may contain 
as much as eight modules. An example is the syringomycin synthetase E, produced by 
Pseudomonas syringae. It is one of the largest know bacterial NRPS and produces 
syringomycin E (Figure 11), an antifungal cyclic lipodepsinonapeptide that inhibits 
growth of Sacchromyces cerevisiae.70 During the early days of NRPS research, the 
dogma of the colinearity rule (the notion that the sequence of an NRP directly reflects 
the linear arrangement of the modules and domains in the enzyme) was believed to be 
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the strategy for controlling natural product biosynthesis in  this system.71-73  NRPSs that 
follow this rule are classified as type A or linear systems.  
 Recent characterizations of NRPS systems have shown that the colinearity rule 
does not apply to all NRPSs. For instance, the cyclic lipoheptapeptide surfactin (Figure 
10) is synthesized following this rule;74 however, the colinearity rule falls apart when 
applied to the gramicidin S (Figure 11) synthetases GrsA and GrsB.75-76 GrsA contains 
one module and incorporates one amino acid, whereas GrsB contains four modules that  
 
 
    Figure 11.Some natural products of NRPS origin. 
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activate and load five amino acids into the natural product. This type of NRPS is used 
repeatedly or iteratively and classified as type B or iterative NRPS.73 The third class, 
type C (non-linear) of the NRPS system is more complicated and deviates from the  
classical (C-A-T) arrangement of modules.73 Bleomycin A2 (Figure 11) synthetase, 
BlmIII, has a modular arrangement containing A-PCP-Ox in place of the classical C-A-
PCP arrangement.77  
 The knowledge of the preceding types of NRPS systems has been useful in 
predicting the arrangement of modules and domain in the NRPS templates. However, 
nonfunctional domains cannot easily be predicted based on the primary sequence of the 
natural product.78 The biosynthetic logic of NRPSs with unusual domain architecture 
cannot easily be explained by the sequence of the natural product. This makes 
biochemical characterization imperative for better understanding of the logic of these 
unusual enzymes. 
 
TERPENES AND ALKALOIDS 
Terpenes  
Terpenes are natural products that are built up from isoprene subunits. They are 
widespread in nature and are the main constituents of plant essential oils. The name 
originated from turpentine, the so called “resin of pine trees” that flows upon cutting or 
carving the bark of pine trees. Many terpenes are hydrocarbons but may also exist as 
terpenoids containing alcohols, aldehydes, ketones, carboxylic acids, ethers, esters or 
glycosides as functional groups. Plants produce different volatile terpenes to attract 
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specific insects for pollination or to repel certain animals that could eat these plants.79 
There are other terpenes that play roles in growth regulation in plants.79  
Terpenes are classified based on the number of isoprene units (C) n, called the 
isoprene rule. Hemiterpenes contain single isoprene unit (isovaleric acid, prenol), 
monoterpenes contain 10-carbon (citral, geraniol, camphor, limonene, menthol), 
diterpenes contain 20-carbons (taxols, retinal, retinol, phytol), sestererpenes contain 25-
carbons (geranylfarnesol), triterpenes contain 30-carbons (squalene, lanosterol), 
tetraterpenes contain 40-carbons (carotenes). Polyterpenes are made up of many units of 
isoprene, an example of which is rubber.80 Isoprene units may be joined head-to-tail or 
tail-to-tail to form linear chains or re-arranged to form ring compounds.81 The reactive 
isoprene units are isopentenyl pyrophosphate/diphosphate (IPP) and dimethylallyl 
pyrophosphate (DMAPP). There are two possible routes to the formation of IPP, namely 
the mevalonate and the non mevalonate pathways. Three molecules of acetyl-coenzyme 
A (CoA) are used in mevalonate pathway to form IPP, and this pathway occurs in 
mammals and yeasts.81 Two acetyl-CoA molecules are initially combined in a Claisen 
condensation to give acetoacetyl-CoA, and the last molecule is incorporated by 
stereospecific aldol addition to produce 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). 
HMG-CoA undergoes dehydration, reduction, decarboxylation and phosphorylation to 
form IPP.81 Figure 12 illustrates the biosynthesis of IPP via the mevalonate pathway. 
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Figure 12.Mevalonate biosynthesis pathway of isopentenyl pyrophosphate (IPP). 
 
The non-mavelonate or mavelonate-independent pathway to the biosynthesis of 
IPP starts with a thymine pyrophosphate (TPP)–mediated condensation of one unit of 
pyruvic acid and one unit of glyceraldehyde-3-phosphate to give 1-deoxy-D-xylulose 5-
phosphate. This intermediate undergoes several rearrangement and reduction steps to 
produce IPP.82 The deoxy-xylulose phosphate pathway to IPP is illustrated in Figure 13.   
Head-to-tail condensation of IPP and DMAPP (Figure 14) leads to the formation of 
geranyl pyrophosphate (GPP). Condensation of IPP and DMAPP is catalyzed by 
farnesyl diphosphate synthase which can also catalyze the addition of isoprene units unto 
GPP to produce up to sesterterpenes, C25.
83 Triterpenes (C30), however, are not produced 
by the addition of IPP to the growing chain. Two molecules of farnesyl pyrophosphate 
are instead joined tail-to-tail to yield a squalene, an example of a triterpene (Figure 15). 
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Figure 13.The deoxy-xylulose phosphate pathway for IPP. 
 
Carotenoids 
Carotenoids are an important class of terpenoids because they play a significant 
role in energy-transfer process such as photosynthesis. They are formed by the tail-to-tail 
coupling of two molecules of geranylgeranyl diphosphate (GGPP). Lycopene (Figure 
16), one example of carotenoid, is a class of anti-oxidant that acts by scavenging free 
radical species within the human body.84 Lycopene is 100 times more effective in 
quenching singlet-oxygen species than vitamin E (Figure 16).85 It is an intermediate in 
the biosynthesis of β-carotene (Figure 16), a precursor to vitamin A.  
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            Figure 14.Condensation of IPP and DMAPP. 
 
 
             
                   Figure 15. Tail-to-tail condensation of  FPP in squalene biosynthesis. 
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  Figure 16.Structures of carotenoids, lycopene, vitamin E and β-carotene. 
 
 β-carotene can be enzymatically cleaved by the β-carotene 15,15’-
monoxygenase to form two molecules of retinal (Figure 17).86-88 The reduction of  
 
 
Figure 17.Enzymatic cleavage of β-carotene to retinal and conversion to retinol. 
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retinal, produces retinol commonly known as vitamin A, which plays a key role in signal 
transduction in the vision cycle (Figure 18).89 Some of the vision cycle intermediates, 
such as all-trans-retinal (ATR) has been shown to accumulate in the rod outer segment 
(ROS) of the human eye. The incomplete digestion of the ROS by the retinal pigment 
epithelium (RPE) results in autoflourescent by-products known as lipofuscins. These 
lipofuscin have been implicated in a disease state known as age-related macular 
degeneration, a leading cause of blindness in people over 60-years of age.90  
 
     
         Figure 18.Human vision cycle. 
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COMBINATORIAL CHEMISTRY & ENGINEERING OF SECONDARY 
METABOLIC PATHWAYS 
Nature has a vast collection of chemists in the form of microorganisms harboring 
millions of specific pathways to produce a wide variety of chemicals. The synthetic 
chemists have contributed significantly in crafting pathways for making some of these 
important compounds in the laboratory. In spite of the advances in synthesis of bioactive 
compounds, disease conditions continue to exert a substantial pressure on mankind to 
bolster the lean resources to combat all these diseases. Combinatorial chemistry was 
introduced to increase the number of different but structurally related molecules that 
could be synthesized in the same reaction steps. The field of combinatorial chemistry 
reached an advanced stage early in 1980s.91 This was marked by a shift from extraction 
of compounds from natural sources to synthesis of large libraries of compounds. The 
advances in the use of nuclear magnetic resonance (NMR) spectroscopy for 
characterization of natural products was an impetus to combinatorial chemistry w,hich in 
turn became the mainstream tool of drug discovery.92 This new method of synthesis of 
pools of chemical compounds necessitated the improvement in purification and 
screening methods.  The labor and time requirements that could have been a major set-
back for combinatorial chemistry were overcome by the use of powerful computer 
simulation for combinatorial synthesis and subsequent high-throughput screens based on 
molecular targets.  
Although combinatorial chemistry has succeeded as a method for optimizing 
structures that were recently approved as therapeutic agents by the FDA, only one de 
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novo combinatorial compound has been approved in the last 30-years.2 Sorafenib 
(Nexavar), a multikinase inhibitor, was developed by Bayer and approved by the FDA 
for the treatment of renal cell and hepatocellular carcinoma.2 One major limitation of 
combinatorial chemistry is that it is not particularly effective as a de novo drug 
discovery tool; however, the capability for structural optimization is tremendous once an 
active natural product skeleton is discovered.93  
Total synthesis of complex natural products, although often successful for use as 
a model, has limited practical and economic value.178 The dependence of the large-scale 
production of synthetic drugs on petroleum-derived precursors has also raised the issue 
of sustainability and environmental impact of hazardous chemical wastes generated by 
these methods. Human beings as adherents of Le Chatelier’s principle have resorted to 
emerging methodologies and technologies in the production of important natural 
products.  
The endogenous biosynthetic pathways in microbes are precise and efficient; less 
harmful waste is generated and the processes are in tune with the global order of “green 
environment”. Combinatorial biosynthesis or metabolic engineering involves the rational 
manipulation of genes governing the secondary metabolic pathways in microorganisms 
to increase the structural diversity and activity of the new products.94-96  
Gene clusters encoding many natural products (Figure 19) have been 
characterized and whole-genome sequencing, which has become increasingly fast and 
cheap has uncovered hundreds of cryptic or “orphan” secondary metabolic pathways.97 
This suggests that the potential for discovery of natural products is underestimated by 
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the number of natural products described to date. Rational manipulations by insertion, 
deletion or swaping of elements of biosynthetic gene clusters are possible, and they 
greatly increase the possibilities of new natural products.  
   The analysis of modular type I PKS has shown that the total number of modules 
determines the polyketide chain length before cyclization, whereas the catalytic domains 
contained in each modules control the level of oxidation of the polyketide.98,99 Some of 
the achievements so far recorded in combinatorial biosynthesis include structural 
diversity in a polyketide system made by introducing a loading domain in the first 
module that could accept a wide range of starter units, such as 3-amino-5-
hydroxybenzoic acid, isobutyryl CoA and 3, 4-dihydroxycyclohexanecarboxylic acid.100 
Ring-contraction of polyketides has been effected by movement of the terminal 
thioesterase to different modules of the PKS.101,102  The analogues of parent polyketides 
have also been produced by deletion, insertion and switching of catalytic domains and 
modules.103-105  
Successful combinatorial biosynthesis will not be possible if multi-modular 
enzymes cannot transfer the intermediate from the last module to the downstream 
module that will further tailor the intermediate. Docking-domain studies, which involves 
a computer-simulated replacement of specific residues and analysis of the activity of the 
engineered enzymes have helped in understanding the requirement for transfer of 
intermediates between unrelated modules.106,107 Combinatorial biosynthesis in the 
polyketide system has had quite some difficulties to overcome, and developing high-
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throughput combinatorial strategies with multi-modular enzymes still remains a 
challenge. 
 
 Figure 19. Structures of natural products whose gene clusters have been identified. 
Many organisms producing natural products are understudied and introducing 
DNA into them is difficult. Some of these organisms are slow-growing, unculturable, or 
do not contain systems for regulated gene expression.108-111 The multi-modular enzyme 
systems present even greater difficulties because of their extraordinarily large sizes (35 
to > 200kb) and lack of conserved restriction sites to facilitate domain or module 
switches.111  
 30 
A breakthrough in high–throughput combinatorial biosynthesis was achieved in 
the PKS gene set of the 6-deoxyerythronolide B synthase, DEBS (Figure 6). Fourteen 
modules from eight PKS clusters were synthesized with optimized codons for expression 
in E.coli, and they were shuffled into 154 bimodular combinations. Almost 50% of the 
combinations successfully mediated polyketide biosynthesis in E.coli.112 What these 
findings suggest is that the inter-domain/module architecture should be understood for 
successful combinatorial biosynthesis involving domain or module switching. The 
design and inclusion of appropriate inter-module or domain linker sequences is crucial 
for transfer of modules between these units109. 
 
AZINOMYCIN B 
Azinomycins B is a secondary metabolite first isolated from S. sahachiroi as 
carzinophlin A.113 Three decades later azinomycin B, its analogue azinomycins A, and 
expoxamide (Figure 20) were isolated from S. griseofuscus.114 With improvement in the 
purification methods and spectroscopic analysis, carzinophilin A was found to be the 
same compound as azinomycin B. Azinomycin B is of specific interest to the research 
community since it exhibits anticancer and antibacterial properties.113-115 The anticancer 
activity is ascribed to the DNA cross linking effect arising from the aziridine and 
epoxide moieties of azinomycin B. It was initially concluded that since epoxamide 
lacked the 1-azabicyclo-[3.1.0] ring, the antibacterial and antitumor activities should be 
negligible. It was later found that epoxamide exhibited a strong cytotoxic effect [IC50 = 
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0.0036µg/mL] against P388 murine leukemia.116 The antitumor activity was weak in an 
in vivo antitumor assay against P388 murine leukemia. 
 
 
 Figure 20.Structures of azinomycin A, azinomycin B and epoxamide.  
 
 In vitro studies have shown that aziomycin B forms inter-strand cross-links with 
DNA via the electrophilic C10 and C21 carbons of azinomycin and the N7 positions of 
suitably disposed purine bases (Figure 21).117 
 
                             
Figure 21.Azinomycin interaction with duplex DNA. 
 
 
 32 
BIOSYNTHESIS OF AZINOMYCIN B 
The biosynthesis of azinomycins is of utmost importance to the science 
community because of its unique architecture. It contains the azabicyclo [3.1.0] hexane 
ring and is one of the few compounds (Figure 22) containing the three member nitrogen 
heterocycle (aziridine ring). The biosynthetic gene clusters of azinomycin B, mitomycin 
C, azicemicin A and maduropeptin have been discovered but the biosynthetic route to 
the azabicyclic ring has not been successfully established.29,118-120 The biosynthetic 
reactions leading to the epoxide moiety of azinomycin B are also not well understood. 
The structures of azinomycins A and B are suggestive of hybrid PKS and NRPS 
biosynthetic origins. The naphthoate moiety of azinomycin B is analogous to that in 
neocarzinostatin, an anti-cancer compound with a gene cluster encoding an iterative type 
I PKS.121 
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 Figure 22.Structures of some aziridine-containing natural products. 
 
A milestone in understanding of the precursor origin in azinomycin B 
biosynthesis has been reached through the use of isotopically-labeled precursors in 
fermentation cultures. Details of some of these studies and their results will be pointed 
out in later chapters. 
 
STATEMENT OF PURPOSE 
     An overview of natural product biosynthesis has been presented in the 
introduction. Against this backdrop, the goals of this study are to identify the roles and to 
characterize the genes involved in the azinomycin biosynthesis so as to enhance future 
bioengineering effort and the design of a custom drug delivery system against cancer.  
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CHAPTER II 
GENETIC DISRUPTION OF ORF10, A DEHYDROGENASE AND THE 
  
IMPACT ON AZINOMYCIN PRODUCTION 
 
INTRODUCTION 
     Azinomycins (Figure 23) are antitumor agents that contain an epoxide moiety 
and an aziridino pyrrolidine (1-azabicyclo [3.1.0] hexane) ring system.113,114 Although 
mitomycin C is already in use in cancer therapies, azinomycin B shows similar 
antitumor activities at much lower doses but has been limited by natural product 
availability.115 In vitro studies have shown that these agents form interstand cross-links 
with DNA via the electrophilic C10 and C21 carbons of azinomycin and the N7 
positions of suitably disposed purine bases.121 Biosynthetic studies on the azinomycins 
were initially limited by difficulties with the fermentation system resulting in unreliable 
production of the natural products. Because this limitation persisted, a cell-free system 
was developed to study the in vitro biosynthesis of the azinomycins.123  
 
                                                       
Figure 23.Structures of azinomycin A and B. 
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These investigations led to precursor assignments, 124 sequencing of the genome 
and the identification of the biosynthetic gene cluster in S. sahachiroi (Figure 24).125, 126   
 
   
  Figure 24. Revised azinomycin gene cluster. 
 
The cell-free studies established L-Valine as the precursor in the formation of the 
epoxide moiety.123 
Once we optimized our fermentation procedure, a feeding experiment with 13C-
labeled valine and several advanced precursors was conducted, and a biosynthetic route 
(Figure 25) to the formation of the epoxide moiety in the azinomycins was postulated 
based on these results.125  The compound 3-methyl-2-oxobutenoate (Figure 25) is the 
most advanced precursor of valine that is found to be incorporated into the epoxide by 
feeding experiment.125 However, the valine degradation pathway (Figure 26) suggests 
 36 
that methylacryl-CoA (51), an analogue of 48 could be further modified to 3-
hydroxyisobutyrate (52b), an analogue of 47 by the intervening enzymes. Apart from 
valine, most of these precursors appear to have be been derived from the valine 
degradation pathway. Based on the proximity of ORF10 to the gene cluster (Figure 24), 
we postulated that ORF10 might play a role in azinomycin biosynthesis. A BLAST 
search of ORF10 showed that it has ~ 60 % sequence identity to 3-hydroxyisobutyric 
acid dehydrogenase from E.coli (Appendix). The conversion of compound 52b to 53 is 
thought to represent a shunt system that reduces the valine intermediate flux towards 
azinomycin production. 
      The blockage of shunt pathways to natural products or other metabolite 
production is routinely used to increase the titer of the natural products or metabolites.127 
This chapter explores the use gene disruption of ORF10 to evaluate its role in 
azinomycin biosynthesis. Disruption of 3-hydroxyisobutyric acid dehydrogenase is 
expected to lead to the accumulation of compound 52b, thereby increasing the flux 
towards azinomycin formation. The disruption could also clearly define the end of the 
azinomycin biosynthetic gene cluster. 
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Figure 25.Biosynthetic route to the epoxide moiety in the azinomycins. 
 
Figure 26.Valine degradation pathway.  
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MATERIALS AND METHODS 
Unless otherwise specified, biochemical reagents were purchased from Sigma 
(St. Louis, MO). Oligonucleotide primers were ordered from Integrated DNA 
Technologies (Idtdna), USA, and PCR kit (Phusion DNA polymerase, buffer, dNTPs, 
DMSO), all enzymes and regular DNA ladders were obtained from NEB (Ipswich, MA). 
All PCR was carried out with PTC-200 Peltier Thermal cycler by MJ Research 
(Waltham, MA). All other media, reagents, glassware, petri dishes, dichloromethane and 
dimethyl sulfoxide (DMSO) were purchased from VWR International (West Chester, 
PA). DNA miniprep (QIAprep) and Gel extraction (QIAquick) kits were purchased from 
Qiagen (Valencia, CA). Oligonucleotide primers, plasmids, and bacterial strains used in 
this study are summarized in Table 1. Reverse-phase high performance liquid 
chromatography (RP-HPLC) separations were conducted on a Waters 600 Controller 
equipped with Waters 2487 dual λ absorbance detector ( Milford, MA ) by using a 
Phenomenex Prodigy 5µ C8 (250 x 4.6 mm) column (Torrance, CA). 1H NMR spectra 
were recorded on a Varian Inova 300 (Chemistry Dept., Texas A&M University). 1H 
NMR chemical shifts are reported as δ values in ppm relative to CDCl3 (7.26 ppm) and 
coupling constants (J) are reported in Hertz (Hz). 
Radioactive labeled adenosine triphosphate (32P ATP) was purchased from 
Perkin Elmer (Walthan, MA), and the 1Kb Plus DNA ladder used in Southern 
hybridization was obtained from Life Technologies (Carlsbad, CA). 
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Media Conditions  
All components are per liter of deionized water and autoclaved before use. 
R2YE (Required Growth Factor added/Yeast Extract): Yeast extracts, 4 g; Bacto-
peptone, 4 g; Bacto-tryptone, 2 g; Glucose, 10 g; Sucrose, 103 g; K2SO4, 0.25 g; 
MgCl2.6H2O, 10.12 g; Casaminoacids, 1g; 10 mL KH2PO4 (0.5%); 80 mL CaCl2.2H2O 
(3.68 %); 15 mL L-proline (20 %); 2 mL *Trace element solution; 5 mL NaOH (1N); 25 
mL Tris-HCl (1M, pH 7.5); adjust to pH 6.8 with HCl or NaOH. *Trace element 
solution contained the following components per liter: ZnCl2, 40 mg; FeCl3 •6H2O, 200 
mg; CuCl2 •2H2O, 10 mg; MnCl2•4H2O, 10 mg; Na2B4O7• 10H2O, 10 mg; (NH4)6Mo7O2 
• 4H2O, 10 mg; and deionized water.MS (Manntol/Soy): Mannitol, 20 g; Soy Flour, 20 g 
PS5 (Pharmamedia/Starch): Pharmamedia (yellow cotton seed flour), 5 g; Soluble 
Starch, 5 g, adjust pH to 7 prior to sterilization. LB (Luria-Bertani): Bacto-Peptone, 10 
g; Yeast Extract, 5 g; Sodium Chloride, 5 g. 
 
Cloning of the ORF10 Disruption Cassette 
Genomic DNA was isolated from Streptomyces sahachiroi cultured on R2YE for 
2-days at 30 oC with shaking. The salting out method was used for DNA extraction, and 
the DNA used as template to amplify the 950 base pair regions flanking the target gene, 
Orf10. Primer pair Orf10-UP-F which has a HindIII restriction site and Orf10-UP-R 
containing an XbaI restriction site (Table1) was used in the amplification of the upstream 
region whereas Orf10-DS-F which contained an XbaI restriction site and Orf10-DS-R 
which contained an EcoRI restriction site were used in the amplification of the 
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downstream region. The selective marker gene, thiostrepton (TSR), was amplified from 
a plasmid, pRF, a gift from Rongfeng (Table 1) using the TSR primer pair containing 
XbaI restriction sites in both the forward and reverse direction. Amplification was 
achieved in each case using a cycling condition: 98oC for 30 s followed by 29 iterative 
steps of 98 oC for 10 s, 63 oC for 20 s, 72 oC for 30 s and a final 72 oC for 10 mins. The 
PCR reaction mixtures were separated on a 1% agarose gel, and the desired bands were 
extracted from the agarose using a QIAquick Gel Extraction Kit. Purified PCR products 
were digested with appropriate enzymes and purified on a mini-column packed with 
Sephadex G50 (GE Healthcare, Uppsala, Sweden). An E.coli–Streptomyces shuttle 
vector, pKC1139, a gift from Rongfeng (Table 1) was digested with HindIII and XbaI, 
separated on a 1 % agarose gel, and purified using a QIAqick Kit. Digested upstream 
and pKC1139 fragments were ligated to produce the intermediate plasmid pKC1139-
Orf10-1. pKC1139-Orf10-1 was digested with XbaI and EcoRI, and this fragment was 
ligated to the rear-arm fragment to generate the intermediate plasmid, pKC1139-Orf10-
2. Finally, pKC1139-Orf10-2 was digested with XbaI and ligated to the TSR fragment to 
generate pKC-ORF10-KO. All the ligation steps above were followed by transformation 
of E.coli DH10B (Table 1) and transformants were spread on LB-agar plates containing 
25 ug/mL apramycin and incubated at 37 oC for at least 13 hr to allow for selection of 
positive clones. Positive clones were identified by both restriction digestion and plasmid 
sequencing performed using ABI Big Dye Chemistry at the Gene Technology 
Laboratory, Texas A&M University.  
 
 41 
Conjugal Transformation of Disruption Plasmid 
One positive plasmid, pKC-ORF10-KO was transformed in E.coli S17-1 (Table 
1), spread on LB-agar plates containing 25ug/mL apramycin and incubated at 37 oC for 
at least 13 hr. A solid state culture of S. sahachiroi MS-agar plate medium (mannitol 2 
%; soy flour 2 %; bacto-agar 1.5 % in distilled water) was incubated at 28 oC for 5-days. 
The spores were scraped off the plate with a sterile scraper and suspended in 15 mL 
Falcon tubes containing 2xYT medium (1.6 % tryptone and 1 % yeast extract in distilled 
water) and sterile glass beads. The spores were vortexed for 1 min and filtered through 
sterile cotton followed by heat shock at 50 oC for 10 min. Spores were incubated with 
shaking at 37 oC for 3 hr, centrifuged to pellet the spores, and re-suspended in fresh 
2xYT medium. The spores were centrifuged one more time and re-suspended in 4 mL of 
2xYTmedium. The donor, E. coli S17-1, carrying the disruption construct (pKC-OR10-
KO), was prepared according to standard E. coli competent cell preparation. Cells were 
grown overnight at 37 oC with shaking and used to subculture 5 mL LB medium in a 15 
mL Falcon tube to an OD600, of 0.4. The cells were centrifuged at 5000 rpm for 8 min 
and washed twice with 2xYT medium while maintaining the temperature at 4 oC. 
Finally, the cell pellet was resuspended in 2 mL of 2xYT medium, and 1 mL each of 
donor and recipient cells were mixed and plated on ISP4-agar medium supplemented 
with 10 mg/ml sterile magnesium chloride solution. After 18 hr of incubation at 28 oC, 
the plates were overlaid with 1 mL water containing 0.5 mg nalidixic acid and 1 mg 
apramycin. The S. sahachiroi exconjugants resulting from single crossover of the 
plasmid into the chromosome were first isolated after 5-days. Thiostrepton-resistant; but 
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apramycin-sensitive colonies derived from a second crossover were identified after 10 
rounds of selection on MS-agar plates containing 50 µg/mL thiostrepton. 32P-labeling of 
1kb Plus DNA ladder was carried out according to the Life Technologies protocol using 
T4 DNA polymerase and the 500 bp DNA probe was generated by PCR. Unincorporated 
nucleotides were removed by purification using a Sephadex G-50 spin column. Correct 
replacement of ORF10 was checked by both PCR and Southern hybridization. For 
Southern hybridization, genomic DNA of both the wild-type and ORF10 disrupted 
S.sahachiroi were digested with PvuII restriction enzyme. The digested DNA was 
concentrated by ethanol precipitation and separated on a 1% agarose gel. Hybridization, 
washing and detection were performed according to the protocol in Molecular Cloning, a 
Laboratory Handbook, Volume 1.128 
 
Fermentation and Isolation of Metabolites 
Fermentation of ∆ORF10/S.sah and wild-type S. sahachiroi followed a three 
stage fermentation and extraction protocol.125 The fermentation broth was extracted with 
ethyl acetate and the crude extract subjected to HPLC analysis. Each extract was 
dissolved in 50 % acetonitrile to a concentration of 1 mg/mL and passed through a 0.2 
µm syringe filter. To each filtered solution, 10 µL was withdrawn and diluted ten times; 
20 µL was finally drawn from each sample for RP-HPLC analysis. A linear gradient of 
acetonitrile and water (solvent A = acetonitrile; solvent B = water; 0-1 min 10 % A; 1-14 
min 10 % A to 95 % A; 14-15 min 95 % A; 15-20 min 95 % A to 10 % A; 20-25 min 10 
% A) was used to separate metabolites in a Phenomenex Prodigy 5µ C8 (250 x 4.6 mm) 
 43 
column and a detector set at 254 nm and 320 nm. 1H NMR was carried out using 20 
mg/mL solution of each sample in CDCl3. 
 
RESULTS AND DISCUSSION 
Generation of ORF10 Deletion Mutant 
A thiostrepton antibiotic marker was installed in place of ORF10, a 
dehydrogenase located downstream of azinomycin gene cluster. This was done by 
creating a gene disruption cassette and ligating into the E.coli-Streptomyces shuttle 
vector pKC1139. The resulting plasmid, pKC-ORF10-KO (Figure 27) contained 
sequences homologous to those flanking the ORF10 gene in addition to the selection 
marker gene, TSR. The pKC-ORF10-KO plasmid was first introduced into an E.coli 
donor strain, S17-1, and introduced into wild-type S. sahachiroi by conjugation. 10 
rounds of selection (see methods) for the antibiotic TSR resistance resulted in isolation 
of clones that had lost the shuttle vector, pKC1139 (Figure 27). Figure 27 shows the 
strategy used to achieve ORF10 gene disruption by homologous recombination and MS 
agar plates showing positive colonies generated. Verification of the replacement of 
ORF10 was done by PCR method using two pairs of oligonucleotide primers that 
targeted two different genes. The first target is the TSR gene which is inserted into the 
chromosome in the disruptant and the second target is the ORF10 gene.  When an 
ORF10 gene primer pair (ORF10-F+ORF10-R) was used for PCR, only the wild-type 
genomic DNA produced the expected 900bp PCR product. This showed that the ORF10 
gene has been eliminated in the disruptants. However, when the TSR primer pair (TSR-F 
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and TSR-R) was used for PCR, the disruptants gave the expected 1105 bp PCR product, 
whereas the wild-type strain did not give any PCR product. 
 
Table 1  Bacterial strains, plasmids and primers used in ORF10 study 
Strains, plasmids           Relevant characteristics                                                Reference or source        
or primers                         or primer sequence   
                                               
Strains 
S. sahachiroi         Wild type azinomycin A and 
                              B-producing strain                                                                              ATCC 
E.coli DH10B        General  cloning host                                                                         Epicentre 
E.coli S17-1           Conjugative donor                                                                             Rongfeng* 
∆ORF10/S.sah       S.sahachiroi lacking ORF10                                                             This study 
 
Plasmids 
pKC1139               Streptomyces-E.coli shuttle vector                                                     Rongfeng 
pKC-ORF10-KO   Gene disruption construct                                                                  This study 
 
Primers 
TSR –F                  GCGTCTAGATGATCAAGGCGAATACTTCATATG                 This study 
TSR -R                  CGCTCTAGAATCACTGACGAATCGAGGTCGAG                    This study 
ORF10-UP-F         GTCAAGCTTGGACCCCGAGGGCAACGAGTTCG                   This study 
ORF10-UP-R        GCTTCTAGACCCTCCATGCTCGGAGAGTG                             This study 
ORF10-DS-F         CTGTCTAGACCGTGCGCGGCCACCCGACGTTC                     This study 
ORF10-DS-R        GACGAATTCAGGCCACAGGACACCGTCGCC                         This study 
ORF10-probe-F     CGGCCGGGCATAGGTAGCGTG                                                 This study 
ORF10-probe-R    ACTACTCTCAGAAGTACCCACACT                                          This study 
ORF10-F               GCATGAACGAACAACAGAAC                                                   This study 
ORF10-R               GCGCGGTCCTCGGATGCTG                                                       This study 
 
    * Johns Hopkins University 
 
This confirmed the integration of TSR gene into the chromosome of S. 
sahachiroi. However; the site-specific integration of the TSR gene has to be established 
by Southern blotting. A 500 bp PCR fragment located upstream of the target gene was 
amplified using the primer pairs ORF10-probe-F and ORF10-probe-R (Table 1).This 
PCR probe  as well as the 1 Kb Plus ladder DNA ladder was labeled with 32P-ATP 
according to the Life Technologies protocol. The Southern hybridization strategy and 
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analysis (Figure 27) showed a strong contrast between the wild type and the ORF10-
disrupted strains of S. sahachiroi. Site-specific replacement of ORF10 by the TSR gene 
was confirmed by the presence of 3.1 kb and 1.7 kb fragments in the wild-type and 
mutant DNA respectively.  
 
Fermentation and Analysis of Metabolites 
The spores of mutant and wild-type strains were spread on MS agar plates and 
incubated at 30o C until brownish spores developed (usually 5 -7 days). Fermentation of 
the first and second starter cultures and third-stage fermentation under nutrient-starved 
condition were performed.125 Extraction of the supernatant recovered an amorphous 
yellowish extract. The extract was divided into two equal parts, and one portion was 
used for further purification and the remainder was used as crude sample for HPLC 
analysis. S. sahachiroi produces azinomycin A and B, and purification of the extract 
selectively eliminates the amount of azinomycin A while increasing the percentage 
recovery of azinomycin B. Azinomycin B 1H-NMR spectrum displays a signature 
doublet at about 13 ppm owing to the presence of the enol hydroxyl group derived from 
threonine.125 1H-NMR analysis of purified product from both the wild-type and mutant 
strains showed the presence of the azinomycin B signature doublet at 13 ppm (Figure 
29).  This result indicates that the disruption of ORF10 has little or no effect on the 
production of Azinomycin B. Sample preparation and HPLC conditions were as 
described in the methods and materials section. Reverse phase HPLC profiles (Figure 
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30) of the extract from the mutant and wild-type strains are consistent with the 1H-NMR 
results. 
 
 
Figure 27. Gene disruption strategy for ORF10. (A) Gene disruption plasmid, pKC-ORF10-KO containing 
TSR gene and the flanking regions of target gene, ORF10. (B) Homologous recombination strategy. (C) 
MS-agar plates containing TSR and apramycin antibiotics establishing a double crossover event; mutant 
strains are resistant to TSR while sensitive to apramycin. 
               
Differences in the metabolite profiles exist when extraction is performed with 
different solvents; however, the profiles are quite similar when wild-type and knockout 
strains are compared for the same solvent system. These results indicate that ORF10, a 
4-hydroxyisobutric acid dehydrogenase homologue, is not directly involved in the 
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azinomycin biosynthetic pathway. It also shows that disruption of ORF10 does not lead 
to any substantial increase in azinomycin production. However, an apparent increase in 
azinomycin production could not be detected if the step involving the valine degradation 
 
 
Figure 28.Confirmation of ORF10 gene disruption. (A) PCR and enzyme digestion strategies. (B) PCR 
using primer pairs F1&R1 (lane 1&3) and F2&R2 (lane 2&4). (C) Southern hybridization. 
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Figure 29.1H-NMR analysis of extracts from ORF10 disruptant (A) and wild-type (B) strains. 
 
pathway intermediates is not rate-limiting in the biosynthesis of azinomycin. A minimal 
or no increase in azinomycin production would also be observed if even the 
incorporation of valine degradation products into the biosynthesis of azinomycin is rate-
limiting but the intermediates (Figure 26) are being acted upon by other homologous 
enzymes of the valine degradation pathway. This finding also establishes the boundary 
of azinomycin biosynthetic gene cluster, which contains twelve open reading frames 
(orfs) at the end of the cluster. The promising results of work being done on putative 
azinomycin resistance genes by Felix Yu in our group, and this report demonstrates that 
Orf10 (with double strike) and the genes downstream, orf11 and orf12 (Figure 31) lie 
outside the gene cluster. 
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  Figure 30.RP-HPLC analysis of S.sahachiroi wild-type and ORF10 disruptant. 
  
 
 
   
         
Figure 31.Revised azinomycin gene cluster showing boundary of the gene cluster. 
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CHAPTER III 
PROBING THE ROLE OF aziW, A LYSINE BIOSYNTHETIC GENE (lysW) 
HOMOLOGUE IN AZINOMYCIN PRODUCTION   
 
INTRODUCTION 
The studies on azinomycin biosynthesis have continued to shed light on how 
nature stitched together this complex architectural structure. Feeding experiments with 
isotope-labeled precursors have shown that L-valine, L-threonine and L-glutamic acid 
are incorporated into azinomycin, whereas L-lysine is not.123 L-valine is incorporated 
into the epoxide moiety and L-glutamic acid is incorporated into the azabicycle portion. 
L-threonine is found in the enol fragment of azinomycin B, which distinguishes 
azinomycin A from B (Figure 32). Based on the analysis of the draft genome sequence 
of S. sahachiroi by J. Foulke-Abel (Watanabe’s group) and information gleaned from 
the azinomycin biosynthetic gene cluster,29 a hypothetical path to the formation of the 
azibicyclic moiety using L-glutamic acid as a precursor  was proposed (Figure 33). The 
enzymes involved in the proposed pathway have high sequence homology to those 
involved in bacterial lysine biosynthesis (Figure 34A) through the α-aminoadipic acid 
(AAA) pathway and arginine biosynthesis.129 A putative open reading frame (ORF) that 
lies between aziC7 and aziC4 (Figure 34B) was discovered in the azinomycin gene 
cluster. This ORF had previously gone unnoticed in the azinomycin gene cluster. It 
encodes a protein of 59 amino acids that shows 46 % amino acid sequence identity to 
lysW from T. thermophilus, including four conserved cysteine residues and the C-
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terminal EDWGE sequence.130 The disruption of lysW in T. thermophilus resulted in 
lysine auxotrophy, and reconstitution of all the enzymes in Figure 32A except lysW was 
negative for lysine production.130 This suggested that lysW is a critical enzyme in lysine 
biosynthesis in T. thermophilus.  
     Arginine biosynthesis in bacteria commonly starts with the protection of the α-
amino group of glutamate by an acetyl group through a reaction catalyzed by N-
acetylglutamate synthase, argJ (Figure 31).131,132 This reaction produces N-
acetylglutamate and avoids an undesirable cyclization to form Δ1-pyroline-2-carboxylate 
(Figure 34).130-132 AziC2 is another gene in the azinomycin gene cluster; it is 
homologuous to lysX in T. thermophilus. lysX is involved in lysine biosynthesis in this 
organism. Recent experiments in our group showed that aziC2 is capable of modifying 
both glutamate and α-amino adipic acid with an acetyl group (unpublished work by D. 
Simkhada, Watanabe’s group). However, lysX encoded by T. thermophilus failed to 
catalyze the modification of α-amino adipic acid with an acetyl group.128 
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Figure 32. Some of the precursors that are incorporated into azinomycin. 
 
 
 
    Figure 33.Proposed biosynthetic pathway of the azabicyclic ring. 
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Figure 34. Lysine biosynthesis and location of aziW in azinomycin gene cluster. (A) Lysine biosynthesis 
in bacteria using alpha amino adipic acid (AAA). (B) Portion of aznomycinB gene cluster showing 
position of aziW. 
 
 
 
It was discovered that lysX uses a C-terminal glutamate of lysW as the acceptor 
of α-amino adipic acid. It is suggested, based on experimental evidence, that lysX 
activates the carboxyl group of C-terminal glutamate of lysW through phosphorylation 
using ATP and ligates it to the amino group of α-amino adipic acid (Figure 35) thereby 
avoiding the formation of a cyclic compound, Δ1-piperidine-2-carboxylate, Pip2C 
(Figure 35). Crystallization of lysW with a bound α-aminoadipic acid and co-
crystallization of lysW with lysZ confirmed the role of lysW in T.thermophilus as a 
carrier of α-aminoadipic acid in lysine biosynthesis.133 lysW in the lysine biosynthetic 
clusters of selected bacteria and archea (Figure 36) is located next to, and upstream of 
lysX. However, it is located upstream, but not next to lysX in the azinomycin gene cluster 
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(Figure 36). Lysine is the only known proteinogenic amino acid that has two distinct 
biosynthetic pathways: the diaminopimelate (DAP) pathway in plants, bacteria and 
lower fungi, and the α-aminoadipate pathway in higher fungi.134 
 
              
 Figure 35.Enzymatic activities of lysW & lysX and structures of some truncation products of arginine and 
lysine biosyntheses. (Arginine (pyroline-2-carboxylate);  lysine ( piperidine-2-carboxylate). 
 
 
 
Figure 36.Comparison of gene orientation of lysine biosynthetic gene clusters. Homologues of lysW, lysX, 
lysY, lysZ, lysJ and lysK are color-coded as shown in the legend. Genomic sequence information used is 
for S.sahachiroi, T.thermophilus, D. radiodurans, S. tokodaii, P. horikoshii and A. premix.130  
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Lysine is not known to serve as a precursor of azinomycin biosynthesis. It is intriguing 
that aziW, a putative lysine biosynthetic enzyme, is clustered with other azinomycin 
biosynthetic enzymes. It is also known from the unpublished draft genome sequence of 
S. sahachiroi (Watanabe)126 that this microorganism harbors a several genes involved in 
lysine biosynthesis through the diaminopimelate (DAP) pathway. The aim of this 
experiment is to probe the possible role of this largely forgotten gene, aziW, in 
azinomycin production. 
            
MATERIALS AND METHODS 
Unless otherwise specified, biochemical reagents were purchased from Sigma 
(ST Louis, MO). Oligonucleotide primers were ordered from Integrated DNA 
Technologies (Idtdna), USA while the PCR kit (Phusion DNA polymerase, buffer, 
dNTPs, DMSO), all enzymes and regular DNA ladders were obtained from NEB 
(Ipswich, MA). All PCR reactions were carried out with a PTC-200 Peltier Thermal 
cycler by MJ Research (Waltham, MA). All other media and reagents were purchased 
from VWR International (West Chester, PA). DNA miniprep (QIAprep) and Gel 
extraction (QIAquick) kits were purchased from Qiagen (Valencia, CA). The RNA 
extraction kit (RNeasy Mini Kit) was obtained from Qiagen (Valencia, CA) and the 
Northern hybridization kit (NorthernMax) was purchased from Ambion, a subsidiary of 
Life Technologies (Grand Island, NY). Oligonucleotide primers, plasmids and bacterial 
strains used in this study are summarized in Table 2. Reverse phase high performance 
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liquid chromatography (RP-HPLC) separations were conducted on a Waters 600 
controller equipped with Waters 2487 
 
Table 2  Bacterial strains, plasmids and primers used in aziW study 
Strains, plasmids           Relevant characteristics                         Reference or source        
or primers                         or primer sequence   
                                               
Strains 
S. sahachiroi                 Wild type azinomycin A and 
                                       B-producing strain                                                             ATCC 
E.coli DH10B                General  cloning host                                                         Epicentre 
E.coli S17-1                   Conjugative donor                                                             Rongfeng* 
∆LysW/S.sah               S.sahachiroi lacking LysW                                                 This study 
+LysW/S.sah              ∆LysW/S.sah + LysW                                                          This study                 
 
Plasmids 
pKC1139                     Streptomyces-E.coli shuttle vector                                        Rongfeng* 
pSET-152                    Streptomyces protein expression vector                                Sohng* 
pKC-LysW-KO         Gene disruption construct                                                       This study 
pSET-152-LysW        LysW Complementation construct                                         This study 
 
Primers 
TSR –F                 GCGTCTAGATGATCAAGGCGAATACTTCATATG            This study 
TSR -R                  CGCTCTAGAATCACTGACGAATCGAGGTCGAG             This study 
LysW-UP-F          GTCAAGCTTCGGCGCGCAGGGCGCAGCGGTGCT           This study 
LysW-UP-R          GCTTCTAGACCCTCCATGCTCGGAGAGTG                       This study 
LysW-DS-F           CTGTCTAGATCGTGAAGGTGAGCGTCGTCG                    This study 
LysW-DS-R          GACGAATTCCGGCGAGCGCCAGTTCGGCCA                    This study 
LysW-probe-1-F    CATCGTGGCGAAGGTGGCC                                                 This study 
LysW-probe-1-R    CAAGTTCGCGGCGTTCGCC                                                  This study 
LysW-F(probe-2)   ATAGGATCCAGGAGGCAACACATGACTACG                  This study 
LysW-R(probe-2)  TCTAGACTCGCCCCAGTCCTCTTCGACCTC                      This study 
LysW-probe-3-F    CCCGCAGCACCCGCGCCGTG                                               This study 
LysW-probe-3-R    CCACAGCCGCTCTTGCTCG                                                  This study     
LysW -F                 GCCATGCCCACCCCAAGCT                                                  This study     
LysW-R                  CGGCGTTGTAGACCCGGAAG                                              This study   
aziC3-F                   GTGAACACGGCCCGTCCG                                                    This study 
aziC3-R                   GTACGGTCCGGCCGTCCTG                                                  This study 
aziC10-F                 CAGCGCACCGCCGACCGT                                                    This study 
aziC10-R                 AGCCGATGCCGATACGTC                                                    This study                                                 
 
*Prof. J.K.Sohng, Institute of Biolmolecular Reconstruction, Sunmoon University, South Korea 
* Rongfeng- Johns Hopkins University. 
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 dual λ absorbance detector ( Milford, MA ) by using a Phenomenex Prodigy 5µ C8 (250 
x 4.6 mm) column (Torrance, CA). Radioactive labeled Adenosine Triphosphate (32P 
ATP) was purchased from Perkin Elmer (Walthan, MA), while the 1 Kb Plus DNA 
ladder used in southern hybridization was obtained from Life Technologies (Carlsbad, 
CA). 
 
Media Conditions  
All components are per liter of deionized water and autoclaved before use. 
R2YE (Required Growth Factor added/Yeast Extract): Yeast extracts, 4 g; Bacto-
peptone, 4 g; Bacto-tryptone, 2 g; Glucose, 10 g; Sucrose, 103 g; K2SO4, 0.25 g; 
MgCl2.6H2O, 10.12 g; Casaminoacids, 1g; 10 mL KH2PO4 (0.5%); 80 mL CaCl2.2H2O 
(3.68 %); 15 mL L-proline (20 %); 2 mL *Trace element solution; 5 mL NaOH (1N); 25 
mL Tris-HCl (1M, pH 7.5); adjust to pH 6.8 with HCl or NaOH. *Trace element 
solution contained the following components per liter: ZnCl2, 40 mg; FeCl3 •6H2O, 200 
mg; CuCl2 •2H2O, 10 mg; MnCl2•4H2O, 10 mg; Na2B4O7• 10H2O, 10 mg; (NH4)6Mo7O2 
• 4H2O, 10 mg; and deionized water.MS (Manntol/Soy): Mannitol, 20 g; Soy Flour, 20 g 
PS5 (Pharmamedia/Starch): Pharmamedia (yellow cotton seed flour), 5 g; Soluble 
Starch, 5 g, adjust pH to 7 prior to sterilization. LB (Luria-Bertani): Bacto-Peptone, 10 
g; Yeast Extract, 5 g; Sodium Chloride, 5 g. MOPS, 15 g; Trace elements, 10 
mL.Dissolve in 1-liter and autoclave. RNase free water was prepared by incubation of 2 
liter solution containing 0.1 % diethyl pyrocarbonate, DEPC (Sigma-Aldrich) at 42 oC 
for 24 hr followed by autoclave. 
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Minimal Media: Prepare 5X M9 salt by mixing Na2HPO4.12 H2O 85.7 g, KH2PO4 15.0 
g, NaCl 2.5 g in 1000 ml of milli-Q and autoclave. Dissolve 5 g (NH4)2SO4 in 15 ml of 
H2O, sterile filter. Prepare trace elements solution by dissolving  1 g EDTA, 29 mg 
ZnSO4.7H2O, 198 mg MnCl2. 4H2O, 254 mg CoCl2. 6H2O, 13.4 mg CuCl2  and 147 mg 
CaCl2 in 100 ml of milli-Q and autoclave. Prepare each of the following solutions in 
milliQ water separately and sterile filter: 20 % (w/v) glucose: 25 g in 100 ml, 0.1 M 
CaCl2.2H2O: 1.47g in 100 ml, 1M MgSO4.7H2O:24.65g in 100 ml, 10 mM FeSO4.7H2O: 
140 mg in 50 ml (prepare fresh), 1 % thiamine: 500 mg in 10 ml (prepare fresh). For 1 
liter M-9 media, mix 200 ml of M-9 salts, 3 ml of (NH4)2SO4, 1 ml of CaCl2.2H2O, 1 ml 
trace elements, 20 ml glucose, 1 ml MgSO4.7H2O, 1 ml FeSO4.7H2O and 2 ml thiamine. 
 
Cloning of the aziW Disruption Construct 
Genomic DNA was isolated from Streptomyces sahachiroi cultured on R2YE for 
2-days at 30 oC and 250 rpm shaker using the salting out method. This DNA was used as 
template to amplify the 950 base pair regions flanking the target gene, LysW. Primer 
pair (LysW-UP-F which has a HindIII restriction site and LysW-UP-R containing an 
XbaI restriction site, Table 2) was used in the amplification of upstream region. LysW-
DS-F which contained an XbaI restriction site and LysW-DS-R that contained an EcoRI 
restriction site was used in the amplification of the downstream region. The selective 
marker gene, thiostrepton (TSR) was amplified from a plasmid, pRF, a gift from 
Rongfeng (Table 2) using the TSR primer pair containing an XbaI restriction sites on 
both the forward and reverse direction. Amplification was achieved as follows: 98 oC for 
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30 s followed by 29 iterative steps of 98 oC for 10 s, 63 oC for 20 s, and 72 oC for 30 s 
and a final 72 oC for 10 min. The PCR reaction mixtures were separated on a 1% agarose 
gel and the desired bands extracted from the agarose using a QIAquick Gel Extraction 
Kit. Purified PCR products were restriction digested with appropriate enzymes and 
purified on a mini-column packed with Sephadex G50 (GE Healthcare, Uppsala, 
Sweden). An E.coli – Streptomyces shuttle vector, pKC1139, a gift from Rongfeng 
(Table 2) was digested with HindIII and XbaI, separated on a 1 % agarose gel and 
purified using the QIAqick Kit. Digested upstream and pKC1139 fragments were ligated 
to produce intermediate plasmid pKC-LysW-UP. This was digested with XbaI and 
EcoRI and the fragment ligated to the rear-arm digest to generate intermediate plasmid 
pKC-LysW1. Finally, pKC-LysW1was digested with XbaI and ligated to TSR fragment 
to generate pKC-LysW-KO. All the ligation steps above were followed by 
transformation in E.coli DH10B (Table 2) and transformants were spread on LB-agar 
plates containing 25 µg/mL apramycin and incubated at 37 oC for at least 13 hr to allow 
for selection of positive clones. Positive clones were identified by both restriction 
digestion and plasmid sequencing performed using ABI Big Dye Chemistry at the Gene 
Technology Laboratory, Texas A&M University.  
 
E. coli-S. sahachiroi Interspecies Conjugation 
S. sahachiroi was inoculated onto MS-agar plates (mannitol 2 %; soy flour 2 %; 
bacto-agar 1.5 % in distilled water) and incubated at 28 oC for 5-days. The spores were 
scraped off the plate with a sterile scraper and suspended in a 15 mL falcon tube 
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containing 2xYT medium (1.6 % tryptone and 1% yeast extract in distilled water) and 
sterile glass beads. The spores were vortexed for one minute and filtered through sterile 
cotton followed by heat shock at 50 oC for 10 min. Spores were pre-germinated by 
shaking at 37 oC for 3 hr and the tube subsequently centrifuged at 6000 rpm for 10 min 
to pellet the spores. The pellets were re-suspended in fresh 2xYT medium. The spores 
were again centrifuged and re-suspended in 4 mL of 2xYTmedium. The donor, E. coli 
S17-1 carrying the disruption construct (pKC-LysW-KO), was prepared according to 
standard E. coli competent cell preparation.135 The E.coli S17-1 carrying the pKC-
LysW-KO plasmid was grown overnight at 37 oC with shaking and used to subculture 5 
mL LB medium in a 15 mL falcon tube until the optical density, OD600 = 0.4. The cells 
were centrifuged at 5000 rpm for 8 min, washed twice with 2xYT medium while 
maintaining the temperature at 4 oC. The cells were re-suspended in 2 mL of 2xYT 
medium and 1 mL of each of the donor and recipient cells were mixed and plated on 
ISP4-agar medium supplemented with 10 mg/ml sterile magnesium chloride solution. 
After 18 hr of incubation at 28 oC, the plates were overlaid with 1 mL water containing 
0.5 mg nalidixic acid and 1 mg apramycin. The S. sahachiroi exconjugants resulting 
from single crossover of the plasmid into the chromosome were first isolated after 5-
days. Thiostrepton-resistant but apramycin-sensitive colonies derived from a second 
crossover were selected for further confirmation after 5-rounds of selection on MS – 
agar plates containing 50 µg/mL thiostrepton. 
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Generation of 32P-dATP Labeled Gene Probes and Southern Hybridization 
32P-labeling of 1 kb Plus DNA ladder was carried out according to Life 
Technologies protocol using T4 DNA polymerase. Two 500-bp (probes 1 & 3)  
fragments located up and downstream of aziW  respectively and 180-bp (lysW) probes 
were generated by PCR.The PCR consisted of a 20 µl reaction mixture containing 1µL 
32P-dATP in addition to 0.4 mM of each primer (Table 2); 0.25 mM of each of the 4 
dNTPs, 1 μl of plasmid harboring the corresponding template DNA, 1 U of high fidelity 
phusion polymerase (NEB) in its recommended reaction buffer, 10% DMSO and other 
PCR components as described previously. A control PCR was set up under similar 
conditions except with water in place of 1µL 32P-dATP. PCR mixture from the control 
reaction was analyzed for purity on a 1 % agarose gel electrophoresis. Unincorporated 
nucleotides from the PCR containing 1 µL 32P-dATP were removed by purification 
using a Sephadex G-50 spin column and radioactive activity checked with a Gieger 
counter. For Southern hybridization, 40 µg genomic DNA (wild type and LysW 
disrupted S. sahachiroi) were digested with BglII restriction enzyme at 37 oC for 3 hr in 
a 50 µL reaction volume. The digested DNA was concentrated by ethanol precipitation 
and separated on 1 % agarose gel at 80 V for 3 hr. DNA transfer to positive nylon 
membrane (Ambion) was performed by upward transfer method as contained in the 
Molecular Cloning, a Laboratory Handbook, Volume1.128 DNA transfer to the 
membrane (via alkaline transfer) took approximately 6 hr, at which time the set-up was 
disassembled and the membrane agitated in neutralization buffer for 5 min. Pre-
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hybridization and hybridization, washing and detection were performed according to the 
protocol in the Molecular Cloning, a Laboratory Handbook ,Volume 1.128 
 
Construction of Recombinant Integrative Plasmid, pSET152-lysW 
 
For functional overexpression of the aziW gene in Δ aziW S. sahachiroi, a 200-
bp DNA fragment including the entire aziW gene and its upstream ribosome binding site 
(RBS) was amplified by PCR using the wild type S. sahachiroi genomic DNA as a 
template with the primer pair LysW-F and LysW-R (Table 2) containing the restriction 
sites BamHI on the forward and XbaI on the reverse primers. PCR mixture (final volume 
of 20 μl) contained 0.4 mM of each primer, 0.25 mM of each of the 4 dNTPs, 1 μl of 
extracted DNA, 1 U of high fidelity phusion polymerase (NEB) in its recommended 
reaction buffer, and 10 % DMSO. Amplification was performed in a Thermal Cycler 
(BioRad, USA) according to the following profile: 98 oC for 30 s followed by 29 
iterative steps of 98 oC for 10 s, 63 oC for 20 s, 72 oC for 30 s and a final step of 72 oC 
for 10 min. 1 U Taq DNA polymerase (NEB) was added to the mixture and extension 
was carried out in the thermal cycler at 72 oC for additional 10 min. The PCR reaction 
mixtures were separated on a 2 % agarose gel, the desired bands excised from the 
agarose gel and the DNA extracted using a QIAquick gel extraction kit. Purified PCR 
product was ligated into a pGEM T-easy vector (Promega) according to manufacturer’s 
protocol and transformed in E. coli DH10B. Positive clones were selected followed by 
complete nucleotide sequence confirmation by Genetech Lab, Texas A&M University. 
The PCR product was finally subcloned into the pSET152 integrative plasmid containing 
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a strong constitutive promoter, ermE* and the resulting plasmid was designated 
pSET152-aziW. The sequence of this plasmid was verified and the plasmid was 
transformed in E.coli donor strain, S17-1 followed by selection on apramycin plates.  
 
E. coli-S. sahachiroi Interspecies Conjugation 
Conjugation with the streptomyces system was performed as described 
previously except that S. sahachiroi ΔaziW strain was used in place of wild type. Since 
the ΔlysW strain is already resistant to thiostrepton, the conjugation plates were overlaid 
with 1 mL water containing 0.5 mg nalidixic acid, 1 mg apramycin and 1 mg 
thiostrepton. Streptomyces spores that were resistant to both thiostrepton and apramycin 
were selected through one more cycle of incubation on MS-agar plate containing 25 
µg/mL apramycin and 50 µg/mL of thiostrepton. Positive clones were used for 
fermentation. 
 
Fermentation and Isolation of Metabolites 
The spores of mutant, wild type and complement strains were spread separately 
on MS agar plates and incubated at 28 oC until brownish spores developed (usually 5 -7 
days). Fermentation of the first and second stage starter cultures were performed as 
previously described,125 except the volume of the second stage culture was 100 mL 
instead of 2x600 mL. The third stage culture was carried out under nutrient starved 
conditions fermentation was in 2x 2000 mL flask containing 1 L of medium at 28 oC and 
225 rpm for 84 hr. Fermentation broths were extracted with dichloromethane and 
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concentrated in vacuo to recover amorphous yellowish extracts.  The crude extracts were 
analyzed by HPLC. Each extract was dissolved in 50 % acetonitrile to a concentration of 
1 mg/mL and passed through a 0.2 µm syringe filter. To each filtered solution, 10 µL 
was withdrawn and diluted 10 times; 20 µL was finally drawn from each sample for RP-
HPLC analysis. A linear gradient of acetonitrile and water (solvent A = acetonitrile; 
solvent B = water; 0-1 min 10 % A; 1-14 min 10 % A to 95 % A; 14-15 min 95 % A; 15-
20 min 95 % A to 10 % A; 20-25 min 10 % A) was used to separate metabolites with a 
Phenomenex Prodigy 5µ C8 (250 x 4.6 mm) column and a detector set at 254 nm and 
320 nm. Mass spectral analyses of unique RP-HPLC peaks (Appendix) were performed 
at the mass spectrometer facility in chemistry department, Texas A&M University, using 
both APCI and ESI ionization mode. 
 
RNA Isolation and Northern Hybridization 
RNA isolation was carried out according to the manufacturer’s protocol using the 
RNeasy mini kit (Qiagen). Briefly, glycerol stocks of both the S.sahachiroi wild type 
and the aziW deletion mutant were used to inoculate 5 mL of R2YE medium and 
cultured at 28 oC at 250 rpm for 2-days. The starter culture (100 µL) was used to 
inoculate 50 mL of APM medium (dextrose, 60 g; yeast extract, 8 g; malt extract, 20 g; 
sodium chloride, 2 g; MOPS, 15 g; trace elements, 10 mL). The culture flasks were 
agitated at 250 rpm and 28 oC for 24 hr. The bacterial cells were harvested by 
transferring 3x2 mL culture broth of each construct to 15 mL falcon tubes followed by 
centrifugation at 5000 x g for 5 min at 4 oC. The supernatant was decanted and the tubes 
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allowed to warm to room temperature. Bacterial cells were re-suspended in 100 µL of 
TE buffer containing 3 mg/mL lysozyme. The suspension was then transferred to 1.5 mL 
centrifuge tubes and incubated at room temperature for 10 min. Following incubation, 
350 µL of buffer RLT containing 1% beta mercaptoethanol (β-ME) was added and the 
suspension mixed thoroughly by vortexing vigorously. The tubes and its contents were 
spun down at 14,000 rpm for 2 min. The supernatant was transferred to RNase–free 
centrifuges tube and 250 µL of ethanol (95 %) was added. The mixture was applied to 
RNeasy mini spin columns and centrifuged at 14,000 rpm for 2 min. The mini spin 
column was washed sequentially with RW1 and RPE buffers (Qiagen, RNeasy mini 
Handbook). RNA was eluted with 30 µL Rnase-free water. DNase treatment was carried 
out with a TURBO DNA-free kit (Ambion) to remove the contaminating DNA. Northern 
hybridization was performed according to NorthernMax® protocols (Ambion). Briefly, 
10 µg of total RNA per sample was loaded on a 1% agarose-formaldehyde denaturing 
gel in 1× MOPS buffer (Ambion). The separated RNAs were transferred to the 
BrightStar-Plus membrane (Ambion), UV cross-linked and hybridized with 32P-labeled 
DNA probe specific for AziC4 coding sequence (42 °C overnight in ULTRAhyb buffer, 
Ambion). The hybridized membrane was washed twice with high-stringency wash 
solution for 5 min and 15 min. The hybridization signals were detected between washes 
using a Gieger Counter and membrane exposed to an autoradiography plate for 12 hr. 
The autoradiographic image was visualized with a Fuji Phosphoimager (Texas A&M 
University, Biology Department). 
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Reverse Transcription (RT)-PCR Analysis of Genes Downstream of aziW 
RNA isolation and purification was carried out as described previously. RT-PCR 
was performed according to C.M. Watanabe 136 to check the mRNA expression profile 
of the downstream genes following disruption of aziW. Specifically, the expression 
profile of aziC4, aziC3 and aziC10 were monitored. Following RNA extraction, total 
RNA (5µg) was transcribed to single-stranded cDNA by using SuperScript First-Strand 
(Invitrogen). PCR reactions with the cDNA aliquots were conducted with N-
acetytransfrase (aziC2) as an amplification standard. The PCR primers used (Table 2) 
are lysW-probe-1 for aziC4, aziC3, aziC10 and aziC2.  Each amplification cycle was 
conducted as described previously (cloning of lysW disruption construct). 
 
Testing of Lysine Auxotrophy of aziW Mutant 
The growth of the S. sahachiroi, lysW disruptant and wild type strains were 
monitored on both solid and liquid media. Minimal medium agar plates consisted of 0.5 
g L-asparagine, 0.5 g potassium phosphate dibasic, 0.2 g magnesium sulfate, 10 g 
mannitol, 0.01 g iron sulfate and 10 g bacto agar and 1 L of distilled water. Wild type 
and mutant S. sahachiroi were grown on minimal agar plates supplemented with or 
without 0.1 mM sterile filtered lysine at 28 oC for 3-4 days. For examination of lysine 
auxotrophy in liquid culture, the first stage culture was carried out in R2YE as 
previously described. After 2-days, 50 µl of first stage culture was used to inoculate 50 
mL of minimal medium supplemented with or without 0.1 mM lysine at 28 oC and 250 
rpm for 2-3days. Liquid minimal media was prepared by mixing 200 mL of M9 salts 
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(autoclaved solution of 64 g/L sodium phosphate dibasic, 15 g/L potassium phosphate 
monobasic, 2.5 g/L sodium chloride and 5 g/L ammonium chloride.), 2 mL of 1 M 
magnesium sulfate, 20 mL of 20 % glucose, 100 µL of 1 M calcium chloride in 1 L of 
distilled water. 
 
RESULTS AND DISCUSSION 
Generation of aziW Disruptant  
The thiostrepton antibiotic resistance marker (TSR) was introduced in place of 
aziW, a protein homologous to lysW of T. thermophilus in which it has been shown to be 
involved in lysine biosynthesis. The TSR gene was inserted by ligation between the 
genes flanking aziW within the azinomycin gene cluster and the cassette was ligated into 
the E.coli-streptomyces shuttle vector pKC1139. The resulting plasmid, pKC-LysW-KO 
(Figure 37A), contained sequences homologous to those flanking the aziW gene in 
addition to the selection marker gene, TSR. Sequence analysis of pKC-LysW-KO 
plasmid revealed that the TSR gene was placed in an orientation opposite to that of aziW 
and other downstream genes (Figure 34B). PKC-LysW-KO was first transformed into an 
E. coli donor strain, S17-1, and then introduced into wild-type S. sahachiroi by 
conjugation. Several rounds of selection for the antibiotic TSR resistance resulted in 
isolation of clones that had lost the shuttle vector, pKC1139 (Figure 37C). Figure 35 
shows the strategy used to achieve aziW gene disruption by homologous recombination 
as well as the positive colonies that were generated on MS agar plates. Integration of the 
TSR gene into the S. sahachiroi genome was verified by PCR that targeted the TSR gene 
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(Table 3). Only mutant strains produced the expected TSR product from PCR performed 
with aziW mutant genomic DNA (Figure 38) as template. Site-specific integration of the 
TSR gene between the flanking regions of aziW was verified by Southern hybridization. 
Three different probes were used, each targeting different regions of the mutant 
azinomycin gene cluster. Probe-1, 500 bp long, targeted the upstream region of aziW, 
whereas probe-2 and probe-3 are 180 bp and 500 bp long respectively and targeted the 
aziW gene itself and the gene downstream of aziW. The strategy and results of Southern 
hybridization experiments are shown in Figure 36. Probe-1 produced two bands at ~ 8.4 
kb and ~9.3 kb (Figure 38D) for the wild type and aziW mutant respectively. Probe-2, 
however, produced two bands in the wild type and one band in the mutant (Figure 38B). 
One of the two bands in the wild type corresponds to the ~8.4 kb fragment, whereas the 
second band is a low molecular weight DNA that also appeared in the aziW mutant and 
corresponds to the size of aziW. A close observation of band intensities also showed that 
low molecular weight DNA band in the mutant strain is more intense than the 
corresponding band in the wild type. Probe-3 (Figure 38C) produced bands which were 
consistent with those seen with probe-1. Taken together, these results confirm the site 
specific replacement of aziW by TSR selection marker. However, the appearance of an 
intense aziW band in the mutant is suggestive of the presence of another copy of aziW in 
the S. sahachiroi genome. This is strongly supported by the presence of a similar band in 
the wild-type strain as well as the band that represents our target, aziW. 
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 Recombinant Integrative Plasmid, pSET152-lysW 
 
The aziW sequence containing the native ribosome binding site (RBS) was 
cloned into the multiple cloning site of a recombinant integrative plasmid, pSET152, 
under the control of the erythromycin (ermE*) promoter (Figure 39). It was intorduced 
into E.coli DH10B strain, and the plasmid sequence verified. This plasmid was later 
intoduced into the E.coli donor strain, S17-1 and transferred into the aziW mutant strain 
by conjugation as described previously. Positive clones were selected on apramycin 
plates.  
 
 
Figure 37.aziW disruption strategy. (A) aziW mutant plasmid. (B) Homologous recombination strategy. 
(C) aziW mutant strain on both apramycin and thiostrepton selective plates. 
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Fermentation and Characterization of Metabolites   
The spores of mutant and wild-type strains were spread on MS agar plates and 
incubated at 28 oC until brownish spores developed (usually 5 -7 days). Fermentation of 
the first and second stage starter cultures were carried as described previously.124 
However, third stage fermentation was carried out in shake flask under nutrient-starved 
conditions.124 Fermentation in the shake-flask system ensures that conditions were the 
same and creates a good platform for comparison of wild-type and mutant strains. This is 
in contrast to the standard third stage fermentation, in which only a 10-liter fermentation 
could be carried out.  
 
 
Figure 38.Confirmation of aziW disruption. (A) Enzyme digestion strategy. Southern hybridization with 
(B) lysW gene as probe;(C) aziC4 as probe and, (D) aziC7 as probe. 
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The third stage fermentation in all cases was extended by 24 hr and the 
fermentation broth extracted with dichloromethane separated in vacuo, and a crude 
sample was used for RP-HPLC analysis. RP-HPLC conditions are detailed in the 
materials and methods section. 
 
 
Figure 39.Vector diagram of pSET152 and complementation plasmid. 
  
 
 
Genetic disruption of aziW completely abolished the production of azinomycin 
(Figure 40), suggesting that aziW might be a critical element in the biosynthesis. 
Individual peaks from the wild-type were analyzed and their identity confirmed by mass 
spectrometry (Appendix). Complementation of the disrupted gene by integration into the 
genome has been successfully used to restore the production of natural products.134,137,138 
However, complementation in our case failed to restore the production of azinomycin 
(Figure 41) to a detectable level. However, this might be due to the protein not being 
overexpressed. Alternatively, failure of restoration of azinomycin production in the aziW 
knockout by complementation with aziW might suggest existence of polar effects caused 
by the disruption.  
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Figure 40.RP-HPLC analysis of metabolites from S. sahachiroi wild-type (top) and aziW deletion mutant 
(bottom).  
 
 
Figure 41.RP-HPLC analysis of S. sahchiroi aziW complement (top) and aziW deletion mutant (bottom). 
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Organization of lysW Operon and Northern Blot Analysis 
A potential promoter was identified 49 bp upstream of the lysW translation start 
site, ATG, using the bacteria promoter identification software, BPROM 
(http://linuxl.softberry.com/berry.phtml) (Figure 42A). Northern blotting with a 32P-
dATP-labeled probe specific for the aziC4 sequence was conducted, and consistent with 
the speculation of a co-transcription of aziW with another downstream gene, one 
transcript of above 4 kb was observed (Figure 42B).  
 
 
Figure 42.Promoter analysis of aziW sequence and Northern hybridization. (A) Promoter predicted by 
BPROM to drive the transcription of LysW operon.  Underlined letters indicate -35 and -10 regions for the 
putative promoter. Bold letters indicated the predicted start codon (ATG). (B) Northern blot analysis (and 
zoom in) with 32P-labeled probe specific to azic4 sequence. 
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Sequence analysis of the pKC-LysW-KO plasmid showed that the TSR gene was 
integrated in the orientation opposite the lysW operon (Figure 34B). The implication of 
this is that the aziW operon cannot count on the native TSR promoter to efficiently drive 
the transcription of the operon. The promoter and transcription start site of the lysW 
operon were not affected by the gene disruption of aziW. This might imply that 
transcription in the presence of intervening TSR gene sequence would result in at least 
some amount of downstream gene transcripts. However, the preceding outcome is only 
possible if there is no activation of latent rho-dependent terminators in the TSR 
complement sequence.139-141 Most rho-dependent termination message involved 
termination at the end of the bacterial operons;142 however, in vitro transcription studies 
have revealed existence of rho-dependent termination sites within genes.143 A search of 
TSR gene (1056 bp) using free online transcription termination predictor, ARNold: 
finding terminators, did not predict the presence of any terminator in either direction. 
Only one terminator site was predicted for the 63-kb sequence of azinomycin gene 
cluster in both directions.  
 
The mRNA Expression Profile of Genes Downstream of aziW  
Following the disruption of lysW and the inability of lysW complementation to 
restore azinomycin production to a detectable level, the mRNA expression level of the 
downstream genes were profiled. Single-stranded cDNA was generated by the use the 
SuperScript First-Strand and the PCR conditions normalized with aziC2 as an 
endogenous amplification standard. aziC2 was selected as a standard because it is 
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located 17.8 kb downstream of aziW and may not under the control of the same promoter 
as aziW. The PCR of aziC4, aziC3 and aziC10 were performed under the standardized 
condition and equal amounts of PCR mixtures were analyzed on a 1 % agarose gel 
electrophoresis. Of the three genes whose mRNA exression levels were investigated, 
only aziC4 showed similar expression levels in both wild-type and mutant. The 
expression of aziC3 is lower in the aziW deletion mutant compared to the wild-type, 
whereas the expression of aziC10 is not detectable in the mutant. These results are 
shown in Figure 43. What these results suggest is that the replacement of aziW with TSR 
resulted in the transcriptional attenuation of the downstream genes. The impact is much 
stronger the further away the gene is from the transcription start site, which is located, 
upstream of aziW. It follows from this argument that the transcription of other genes 
(aziC8, aziA5, Figure 31) thought to be under the control of the same promoter as aziW 
(Figure 42) might be down-regulated or truncated. This, and a possible low expression 
level of aziW from the complementation plasmid might explain the inability of the aziW 
complementation to restore azinomycin production. 
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Figure 43.The mRNA expression profile of aziW downstream genes. (A) mRNA expression profile of 
downstream genes; C4, C3, C10. (B) Portion of the gene cluster in aziW disruptant showing the 
endogenous amplification standard, C2 located 17.8 kb downstream of aziW. 
 
  
Lysine Auxotrophy in aziW Deletion Mutant  
In order to probe the role of the aziW gene in lysine biosynthesis, a lysine 
auxotrophy experiment was carried out. First stage culture was carried in R2YE medium 
at 28 oC in a shaker. After 24 hr of incubation, 10 µl of each cultured sample was used to 
inoculate 5mL minimal medium, and incubation was continued for additional 24 hr. 
There was no difference in the phenotype of the wild-type or aziW-deleted S. sahachiroi 
with or without lysine after 24 hr. The growth of the cells in liquid media did not reflect 
the lack of a critical element in lysine biosynthesis as previously reported.132 This 
observation supports the earlier indication of an additional copy of aziW by Southern 
hybridization (Figure 38B). It also lends credence to initial findings by isotope-labeled 
precursor feeding experiment, which strongly showed that lysine is not incorporated in 
azinomycin biosynthesis.125 The aziW-deleted strain certainly grows on minimal media 
agar plates; however, growth is stunted and sporulation is very weak (Figure 44). This 
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might suggest that aziW and other lysine biosynthetic homologues are involved in the 
sporulation process.  
 
     
Figure 44.Lysine auxotrophy experiment on minimal media agar plates. (A) supplemented with 0.1mM 
lysine, top – wild type strain; bottom – LysW deletion strain. (B) without supplement, left – wild type 
strain; right – lysW deletion strain.   
 
 
 
Perhaps, aziW deletion has blocked production of some intermediate compounds 
required for sporulation as regulators or maybe components of the spore cell wall.  
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CHAPTER IV 
BIOCHEMICAL EVALUATION OF THE ROLE OF CYTOCHROME P450 
 
(aziC9)  IN AZINOMYCIN  BIOSYNTHESIS 
 
 
INTRODUCTION 
 
      Cytochrome P450 was first discovered over five decades ago when it was reported 
that an enzyme complex located in the liver was able to oxidatively metabolize certain        
xenobiotic compounds.144,145 Shortly after the discovery of P450, a carbon monoxide 
(CO) binding pigment that gave an absorption maximum (λmax) at 450nm was detected 
in liver microsomes.146,147 This pigment was later identified as a hemoprotein of the b-
type cytochrome, hence the name cytochrome P450.148-150 Cytochrome P450 enzymes 
are found in all five biological kingdoms.151 In the mammalian system, P450s are found 
in most tissues; however, a greater proportion is located in the hepatocyte cells of the 
liver.152 Cytochrome P450 enzymes constitute a large family of oxidative heme-
containing proteins that catalyze a wide range of nature’s oxidative transformations. The 
generic type of reaction catalyzed by P450s is hydroxylation. The reaction requires two 
                                    R-H +O2 +2H
+ +2e-                 R-OH + H2O 
electrons (supplied b redox partners), molecular oxygen and two protons. All P450 
enzymes display close structural similarity despite their low sequence identity. In 
prokaryotes, there exists a P450 heme signature motif: F G x G x H/R x C L /A (where x 
is any amino acid residue F is phenyalanine, G is glycine, H is histidine, R is arginine, C 
is cysteine, L is leucine and A is alanine).153 The heme group consists of the 
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protoporphyrin IX and a central iron (III) atom. The protoporphyrin IX consists of a core 
tetrapyrrole ring formed from four pyrrole rings linked by methylene bridges. Each ring 
contains a methyl group side chain and two consecutive rings contain either a propionate 
or vinyl side chain (Figure 45). Several distinct types of enzymes and redox proteins 
have historically been termed cytochromes based on the presence of a heme group in the 
enzymes; however, their primary, secondary and tertiary structures vary markedly.154 
  The use of the term “cytochrome,” as applied to P450s (EC1.14.14.1) is a 
misnomer since these proteins are now regarded as heme-thiolate proteins or enzymes. 
The distinction is that whereas other cytochromes tend to possess at least one histidine 
residue that ligates the heme iron, the P450s ligate iron with cysteine.154 The peroxidases 
that break down hydrogen perioxide to water contain the heme-moiety, but the ligand is 
usually histidine (except in chloroperoxidase which contains cysteine heme and displays 
spectral characters common to P450s).155,156 One distinguishing feature of peroxidases is 
that they possess active sites that have just enough space to bind a single molecule of 
hydrogen peroxide, whereas P450s have larger active sites due to varying size of 
substrates. P450s are grouped into ten different classes based on the type of redox 
partner used by the enzyme (Table 3).157 
 Typical reactions in which P450 enzymes are involved include metabolism of 
foreign compounds, such as drugs, carcinogens and plant products.158 They generally 
promote the conversion of hydrophobic compounds to hydrophilic derivatives to 
enhance their excretion from the body. In secondary metabolic pathways in 
Streptomyces, P450s are typically located within the biosynthetic gene cluster, where 
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they have been shown to increase the structural complexities and bioactivities of natural 
products through the regio- and stereospecific oxidation of precursors.159-162 However, 
the NADPH-dependent redox partners (NADPH-cytochrome P450 reductase and 
ferredoxin) are not usually clustered with the genes encoding the P450 enzymes. Recent 
advances in genome sequencing and other biological tools have revealed a large number 
of genes encoding the P450 enzymes in Streptomyces.163,164 
  Cytochrome P450 enzymes usually function as monooxygenases that insert one 
atom of oxygen from molecular oxygen into a substrate while reducing the second 
oxygen atom to water. This is usually mediated by two-electron transfer from NAD(P)H 
via a flavoprotein or ferredoxin. The activation of molecular oxygen is common to all 
P450s, and this reaction takes place at the heme center. The proposed catalytic cycle of 
P450s is depicted in Figure 46. 165 
 
                                                   
                                   Figure 45.Protoporphyrin IX with a bound iron. 
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Table 3. Classes of P450 systems classified based on components involved in the electron transfer to the P450 
enzyme   
Class/source  Electron transport chain  Localization/ remarks  
Class I  
Bacterial  NAD(P)H ▸  [FdR] ▸ [Fdx] 
*▸  [P450]  
Cytosolic, soluble  
Mitochondrial  NADPH ▸ [FdR] ▸ [Fdx] 
▸ [P450]  
P450: inner mitochondrial 
membrane, FdR: 
membrane associated,  
Fdx: mitochondrial matrix, 
soluble  
Class II  
Bacterial  NADH ▸ [CPR] ▸ [P450]  Cytosolic, soluble; 
Streptomyces carbophilus  
Microsomal A  NADPH ▸ [CPR] ▸ [P450]  Membrane anchored, ER  
Microsomal B  NADPH ▸ [CPR] ▸ [cytb5] 
▸  [P450]  
Membrane anchored, ER  
Microsomal C  NADH ▸ [cytb5Red] 
▸ [cytb5] ▸ [P450]  
Membrane anchored, ER  
Class III  
Bacterial  NAD(P)H ▸ [FdR] ▸ [Fldx] 
▸ [P450]  
Cytosolic, soluble, 
Citrobacter braakii  
Class IV  
Bacterial  Pyruvat, CoA ▸ [OFOR] 
▸ [Fdx] ▸ [P450]  
Cytosolic, soluble, 
Sulfolobus tokadaii  
Class V  
Bacterial  NADH ▸ [FdR] ▸  [Fdx–
P450]  
Cytosolic, soluble, 
Methylococcus capsulatus  
Class VI  
Bacterial  NAD(P)H ▸ [FdR] 
▸ [Fldx–P450]  
Cytosolic, soluble, 
Rhodococcus strain 11Y 
Class VII  
Bacterial  NADH ▸ [PFOR–P450]  Cytosolic, soluble, 
Rhodococcus sp strain 
NCIMB 9784, Burkholderia 
sp., Ralstonia metallidurans  
Class VIII  
Bacteria, fungi  NADPH ▸ [CPR–P450]  Cytosolic, soluble, Bacillus 
megaterium, Fusarium 
oxysporum  
Class IX  
Only NADH dependent, fungi  NADH ▸ [P450]  Cytosolic, soluble, 
Fusarium oxysporum  
Class X  
Independent in plants/mammals  [P450]  Membrane bound, ER  
Redox center key: Fdx- iron-sulfur cluster; FdR- Ferredoxin reductase( FAD); CPR – cytochrome P450 
reductase (FAD, FMN); Fldx – Flavodoxin (FMN); OFOR – 2-oxoacid:ferredoxin oxidoreductase (TPP, 
[4Fe-4S] cluster); PFOR – phthalate-family oxygenase reductase (FMN, [2Fe-2S] cluster); *Fdx – iron-
sulfur cluster of type: [2Fe-2S], [4Fe-4S],[3Fe-4S], [3Fe-4S]/[4Fe-4S].157 
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Figure 46.Proposed catalytic cycle of cytochrome P450. 
 
Applications of Cytochrome P450 
P450s play indispensible roles in both primary and secondary metabolic 
pathways. Drug metabolism and excretion would almost impossible without the 
intervention of P450s. Industrial biotransformations are carried out by P450; well-
established commercial applications of P450 monooxygenase are in the 
biotransformation of steroids. Examples include the Reichstein S to hydrocortisone 
conversion through 11β-hydroxylation mediated by P450 in Curvularia sp, 
transformation of progesterone to cortisone by Rhizopus sp and the oxidation of 
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campactin to pravastatin (blood cholesterol lowering agent) by Streptomyces sp strain Y-
110.166-168 Other areas that have seen increased application of P450s are the 
environmental biodegradation of harmful compounds like pesticides, insecticides and 
other agro chemicals. CYP101 (P450cam) from Pseudomonas putida has been 
successfully used for the environmentally friendly biodegradation of pentachlorobenzene 
in the absence of either surfactant or organic co-solvents.169 Bioremediation of highly 
toxic polychlorinated dibenzo-p-dioxins by hydroxylation was achieved by the use of 
mammalian P450,170 and that of another toxic compound, 2,3,7-trichlorodibenzo-p-
dioxin was effected with a triple mutant CYP102A1 from Bacillus megaterium.171  
      Cytochrome P450s have great potential in biotechnological and other industrial 
applications and giant strides have already been made; however, the co-factor 
requirement in P450 catalysis is a major setback. An enzyme-coupled system for the 
regeneration of NADPH/NADH   is therefore necessary for successful application of 
P450 at the industrial level. Success in the industrial application of P450s also depends 
on an in-depth understanding of the redox partner requirement for each P450. Some of 
these limitations are being addressed by efforts in the recycling of NADH through an 
enzyme-coupled system for the CYP105D1 from Streptomyces griseus using formate 
dehydrogenase.172 
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Cytochrome P450 as Epoxidases 
Cytochrome P450 catalyzes many reactions one of which is the epoxidation of 
olefins across the double bond by insertion of an oxygen atom. In some cases, 
epoxidation result in new compounds of physiological importance being made from 
naturally occurring substrate such as arachidonic acid.173 Some foreign compounds have 
also been known to exert their mutagenic and carcinogenic effects after undergoing 
cytochrome P450-mediated epoxidation.174 However, epoxidation by cytochrome P450 
in natural product biosyntheses have produced compounds with remarkably increased 
potency. Cryptophycins are potent anticancer agents with about 25-analogues; and they 
have isolated from Nostoc sp. ATCC 53789. Studies have shown that CrpE 
(cyctochrome P450) - mediated epoxidation at the C2’ and C3’ of de-
epoxycryptophycin-1 produces cryptophycin-1 (Figure 47), which exhibits >100 times 
more potency than its precursor.175 Genetic disruption of pimD (cytochrome P450) in 
Streptomyces natalensis produced a novel polyene macrolide with decreased antifungal 
activity.176,177 The cytochrome P450 epoxidase, pimD was discovered to convert the 
intermediate, 4, 5-de-epoxypiramicin to piramicin, a 26-member polyene macrolide 
antifungal antibiotic (Figure 47).  
 
 85 
     
         Figure 47.Cytochrome P450 catalyzed epoxidation reactions. 
 
aziC9, a Cytochrome P450 in the Azinomycin Gene Cluster 
The azinomycin gene cluster contains two cytochrome P450 hydroxylase genes, 
aziB1 and aziC9 (Figure 48). The role of aziB1 has been established as being responsible 
for the catalysis of the regiospecific hydroxylation of free 5-methyl-naphthoic acid to 
produce 3-hydroxy-5-methyl-naphthoic acid. The hydroxyl group is later O-methylated 
by az1B2, a SAM-dependent O-methyltransferase to produce the methoxy functionality 
(Figure 49).178 aziC9, on the other hand, has not been characterized and there are three 
oxidation events in the azinomycin B structure (Figure 50) for which no functional 
assignment of enzymes have been carried out. One of these oxidation steps is the 
formation of the epoxide moiety, which is known to strongly contribute to the DNA 
alkylation effect of azinomycin B.117 
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Figure 48.Azinomycin gene cluster showing cytochrome P450 in blue color. 
 
 
 
  Figure 49.aziB1, cytochrome P450 catalyzed hydroxylation of 5-methyl-NPA. 
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Here, we aim to biochemically evaluate the role of the aziC9, cytochrome P450 
in azinomycin B biosynthesis.  
 
                          
  Figure 50.Oxidation steps in azinomycin shown in red color. 
 
MATERIALS AND METHODS 
Cloning, Overexpression and Purification of aziC9  
All chemicals were bought from either Sigma or VWR. aziC9 gene was 
amplified by PCR using the wild type S. sahachiroi genomic DNA as a template with 
the primer pair AziC9-F and AziC9-R (Table 4) containing the restriction sites NdeI on 
the forward and XhoI on the reverse primers. PCR was performed in a final volume of 
20 μl containing 0.4mM  of each primer, 0.25 mM of each of the 4 dNTPs, 1 μl of 
extracted genomic DNA, 1 U of high fidelity phusion polymerase (NEB) in its 
recommended reaction buffer, and 10 % DMSO. Amplification was performed in a 
Thermal Cycler (BioRad, USA) according to the following profile: 98oC for 30 s 
followed by 29 iterative steps of 98 oC for 10 s, 63 oC for 20 s, 72 oC for 30 s and a final 
72 oC for 10 min. 1 U Taq DNA polymerase (NEB) was added to the mixture and  
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Table 4  Bacterial strains, plasmids and primers used in aziC9 study 
Strains, plasmids           Relevant characteristics                         Reference or source        
or primers                         or primer sequence   
                                               
Strains 
S. sahachiroi               Wild type azinomycin A and 
                                    B-producing strain                                                   ATCC 
E.coli DH10B              General  cloning host                                               Epicentre 
E.coli BL21 (DE3)       Expression host                                                        Invitrogen 
  
Plasmids 
pGEM T-Easy              Cloning vector                                                          Promega 
pET24b                           E.coli protein expression vector                                  Invitrogen   
pET24b-AziC9             Protein expression plasmid                                       This study 
Primers  
 
aziC9 -F                          GCCATATGATTATTTCCAAGCCCCCGTTC          This study 
aziC9 -R                         GACTCGAGCCGTACGTGTGCCTCACGAGGA      This study       
 
extension carried in the thermal cycler at 72 oC for 10 min. The PCR reaction mixtures 
were separated on a 1% agarose gel, the desired bands were excised from the agarose gel 
and the DNA extracted using a QIAquick gel extraction kit. Purified PCR product was 
ligated into a pGEM T-easy vector (Promega) according to the manufacturer’s protocol 
and transformed in E.coli DH10B. Positive clones were selected followed by complete 
nucleotide sequence confirmation by Genetech Lab, Texas A&M University. The PCR 
product was finally subcloned into the pET24b (Invitrogen) and the resulting plasmid 
was designated pET24b-AziC9. This plasmid was transformed in E.coli BL21 (DE3) 
(Strategene) cells for inducible expression under a T7 promoter. A 5 mL overnight 
culture in LB Miller media and 50 μg/mL kanamycin was used to inoculate 1 L media 
and grown to 0.7 OD600. The culture was induced with 1 mM IPTG (Sigma) and 0.5 mM 
aminolevulenic acid (Sigma); culture flask was transferred to 16 °C for 24 hr to achieve 
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optimal soluble expression. All remaining steps were performed on ice. Cells were 
collected by centrifugation, resuspended in 30 mL column binding buffer (50 mM Tris-
HCl pH 7.5, 500 mM NaCl, 5 mM imidazole, 5% glycerol, 1 mM β-mercapoethnol 
(BME)) containing 1 mM phenylmethylsulfonyl fluoride, and lysed by sonication with a 
Branson Sonifier 450 (Branson Ultrasonics, Danbury, CT) fitted with a 5 mm microtip, 
output setting 6, duty cycle 50 %, for 8 cycles of 30 sec each. Cellular debris was 
pelleted by centrifugation, and the supernatant filtered with a 0.2 μm filter before 
applying to a pre-equilibrated HisTrap FF 5 mL column (GE Healthcare Life Sciences, 
Piscataway, NJ) at 1.5 mL/min. The column was washed with 300 mL column buffer 
containing 20 mM imidazole, and AziC9 was eluted with 30 mL column buffer 
containing 250 mM imidazole. The eluate was dialyzed by centrifugal ultrafiltration 
(Amicon Ultra-15 Centrifugal Filter Unit, Millipore, Billerica, MA) to a final 
concentration of 1 mg/mL in 50 mM NaH2PO4 pH 7.5, 5 % glycerol. To determine the 
purity of the protein, 10 µL of purified protein was mixed with 10 µl of 2x protein 
loading dye under denaturing condition (125 mM Tris-HCl pH 6.8, 4 % SDS, 20 % 
glycerol, 10 % BME, 0.004 % bromophenol blue). The mixture was boiled for 10 min at 
100 oC, loaded on a 12 % SDS PAGE and separated by electrophoresis at 200 V for 30 
min. The SDS PAGE was stained in Coomasie blue dye by boiling for 45 s and 
destained after 5 min. 
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Carbon Monoxide (CO) Binding Assay 
The absorbance spectra of P420 and P450 were recorded in 50 mM phosphate 
buffer, pH 7.5, using a Genesys 2 spectrophometer (Thermo Spectronic, USA) at 25 oC 
with a 1-cm light path cuvette. P420 was reduced by the addition of 1 mg of pure sodium 
dithionite; CO gas was bubbled into the sample for about 20 s and the tube capped to 
saturate the sample with CO. The absorbance of unreduced P420 was measured versus 
the reduced sample. 
 
aziC9, Cytochrome P450 Assay  
The activity of aziC9 was tested by reaction with the substrate, 3-methyl-2-
oxobut-3-enoate according to the protocol below. 1 µM aziC9, 2 mM substrate, 5 µM 
ferredoxin, and 0.1 U spinach ferredoxin reductase were mixed and reaction volume 
brought up to 200 µL with 50 mM phosphate buffer. The mixture was incubated at 37 oC 
for 3 min followed by the addition of 0.5 mM NADPH and the incubation continued for 
60 min. Reaction mixture was extracted with ethyl acetate and the sample analyzed by 
mass spectrometry under electron spray ionization mode (ESI). 
 
RESULTS AND DISCUSSION 
Expression and Purification of aziC9 
To evaluate the function of AziC9, the gene was cloned into pET24b (Figure 
51A) and overexpressed in E.coli Bl21 (DE3) (Table 4) under the control of the T7 
promoter. Protein purification was performed by the affinity method using a HisTap FF 
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column (see methods). A brownish-yellow protein (Figure 51B) was recovered after 
elution with 250 mM imidazole. SDS PAGE analysis showed an approximately 98 % 
pure protein migrating at about 51 kDa (Figure 51C), a mass which corresponds to the 
calculated molecular weight of AziC9 plus the His6-tag (Mr = 51351). The protein buffer 
was changed to 50 mM phosphate buffer, pH 7.5 and the concentration measured by UV 
absorbance at 280 nm and extinction coefficient of 4630 M-1 cm-1. 1 mL of 2 µM was 
recovered. 
 
 
 
Figure 51. pET24b-aziC9 plasmid and SDS PAGE analysis of aziC9.(A) Expression plasmid, pET24b-
AziC9. (B) Brownish yellow pure aziC9. (C) SDS PAGE analysis of aziC9, M is protein marker while 
lane 1 is purified AziC9. 
 
 
Spectral Properties of aziC9  
Purified aziC9 has a P420 absorbance but it displays a small shift in absorbance 
corresponding to P450 upon reduction with sodium dithionite and carbon monoxide 
(Figure 52). However, the difference absorbance spectra (reduced P420 as control and 
reduced P420 + CO for 20 s as sample) that showed absorbance at above 420 nm cannot 
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be said to have peaked at 450 nm (Figure 52). Overall these results are suggestive of the 
identity of aziC9 as a cytochrome P450. The reduction of P420 under atmospheric 
conditions instead of anaerobic conditions might be responsible for the less-than-
expected CO binding result in aziC9. 
 
 
Figure 52.Carbon Monoxide (CO) binding study of aziC9. (A) Oxidized P420; (B) Reduced P450 + CO 
and P420; (C) difference spectra of reduced P420 and B above. 
 
 
Sequence Alignment of aziC9  
To further confirm that aziC9 is an authentic cytochrome P450, the translated 
amino acid sequence was searched against other bacterial genome sequences using the 
NCBI BLAST tool and some homologous sequence aligned and analyzed by Gene doc 
free software. As expected, aziC9 harbors the signature heme-binding motif containing 
the unique cysteine residue which co-ordinates the heme center (Figure 53). 
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Figure 53.Multiple sequence alignment of aziC9 with its homologues. (S. flav: Streptomyces flavogriseus, 
41% identity; S. tuber: Streptomyces tubercidius, 39% identity; S. cyanea: Saccharomonospora cyanea 
NA-134, 43% identity; A. mirum: Actinosynnema mirum DSM 43827, 45% identity. Heme binding motif 
(AFGXGXHXCXG) is underlined. 
 
 
Protein sequence alignment of aziC9 and other well characterized epoxidases (pimD, 
OleP, CrpE) showed marked reduction in sequence identity (Figure 54). However, the 
unique heme binding motif is conserved is all sequences. This apparent reduction in 
sequence identity may be attributed to differences in substrate requirements for 
individual enzymes. This further identifies aziC9 as a cytochrome P450; maybe more 
specifically, an epoxidase. 
 
 
 Figure 54.Multiple sequence alignment of aziC9 with other P450 epoxidases. PimD from Streptomyces 
natalensis; Olep from Streptomyces antibioticus and CrpE from Nostoc sp. ATCC 53789. Underlined is 
the heme binding motif (See Figure 45). 
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Conversion of 3-methyl-2-oxobut-3-enoate to the Epoxide 
The enzymatic activity of aziC9 was measured by testing its ability to convert 3-
methyl-2-oxobut-3-enoate to the epoxy-3-methyl-2-oxobutanoate. Purified aziC9 was 
incubated with 3-methyl-2-oxobut-3-enoate; the redox partners and NADPH for 60 min 
at 37 oC (see methods) (Figure 55). The ethyl acetate extract of the reaction mixture was 
concentrated in vacuo and subjected to mass analysis. The result is promising but not 
definite owing to the low concentration of enzyme and substrate available at the time. 
The reaction is being optimized and will be repeated to confirm the product of this 
reaction. However, it is not clear at what stage the oxidation takes place in the 
biosynthesis of azinomycin. A preponderance of data support post PKS/NRPS tailoring 
of intermediates by cytochrome P450s. If this is this case here, it is then expected that 
reaction with 3-methyl-2-oxobut-3-enoate, a non-natural substrate of aziC9, might not 
result in any substantial amount of the corresponding epoxide. Gene disruption of AziC9 
still remains one of the most viable routes to the full characterization of this enzyme. 
Disruption would most likely result in the accumulation of an intermediate which could 
be isolated and used as a natural substrate for aziC9. 
 
                                          
                               Figure 55.aziC9 reaction with 3-methyl-2-oxobut-3-enoate. 
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CHAPTER V 
CONCLUSION 
 
            The importance of natural products to the survival of humans and other living 
organisms cannot be over-emphasized. It is still being used extensively in folk medicine 
especially in developing countries. Understanding how microorganisms and plants make 
these complex medicinal compounds is a crucial step in taking advantage of nature’s gift 
to humanity. This era has certainly witnessed an upsurge in evolutionary diseases and 
emergence of superbugs. 
        The advancement in science and technology, and the existing downward trend in 
the cost of sequencing of bacterial genomes marked a shift towards genetic and 
biomolecular approaches toward understanding these biochemical transformations in 
microbes. These efforts are already paying off in terms of successful natural products 
approved as drugs by the FDA and more detailed understanding of many complex 
product pathways. 
         Azinomycin B has continued to attract the interest of researchers since its initial 
discovery due to its biological activity and unique structural features. The identification 
of the biosynthetic gene cluster has inched us closer to the biosynthetic rationalization of 
this complex architectural anticancer/antitumor compound. Until the enzymatic 
transformations leading to the aziridine and epoxyvaline moieties and the entire structure 
are fully understood, the prospect of engineering a more stable and target-specific 
azinomycin B will remain elusive. Our research group’s effort at developing an in situ 
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drug delivery system via a plasmid bearing cancer cell inducible promoter will receive a 
boost when a more complete understanding of  azinomycin biosynthesis is brought to 
bear. 
         Gene disruption of ORF10, a putative dehydrogenase and the analysis of the 
metabolite revealed no apparent change in the production of azinomycin B. The native 
substrate of this enzyme was not biochemically established and this substrate could as 
well be the product of some other enzymatic reactions. The involvement of ORF10 in a 
shunt pathway to azinomycin could not be categorically determined based on the 
foregoing. However, it did firmly confirm that ORF10 is not part of the azinomycin B 
gene cluster. 
       AziC9 was evaluated and shown to be an authentic cyctochrome P450. This 
family of enzymes catalyzes oxidative reactions which increase both the complexity and 
bioactivities of natural product. Full characterization of aziC9 will rely on gene 
disruption and gene complementation followed by the analysis of the metabolites in each 
case. 
      The azinomycin gene cluster contains genes whose products have not been 
characterized. For example, aziW had not been previously annotated and the disruption 
of which abolished the production of azinomycin. Sequence analysis suggests that this 
gene is transcribed as polycistronic RNA with the downstream genes. The mRNA 
expression profile showed a polar effect on downstream genes following disruption of 
aziW. Further studies will be needed to evaluate the role of aziW in azinomycin 
biosynthesis. 
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     Three experiments were discussed here and they open up platforms for the 
further study of azinomycin biosynthesis. These studies established the boundary of the 
azinomycin gene cluster and identified aziC9 as a true cytochrome P450. The 
identification of specific roles of these genes will be invaluable to combinatorial and 
protein engineering groups who are interested in biosynthetic solutions to bioactive 
compounds. 
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APPENDIX 
 
 
 
 
Figure 56. Multiple sequence alignment of ORF10 with its homologues. (S. sp. Mg1; 84% identity, 
 S. griseoflavus Tu4000; 85% identity, S. flavogriseus ; 84% identity and S. hygroscopicus ;  
81% identity). Co-factor NAD+/NADP+ bindings motif is underlined. 
 
 
 
 
 
 
 Figure 57.Mass spectrum of azinomycin B (peak B) collected from RP-HPLC. 
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  Figure 58.Mass spectrum of azinomycin A (peak A) collected from RP-HPLC.  
 
